Mäntylä R, Männistö PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol (1984) 22, 626–9.	6389377
Singhvi SM, McKinstry DN, Shaw JM, Willard DA, Migdalof BH. Effect of food on the bioavailability of captopril in healthy subjects. J Clin Pharmacol (1982) 22, 135–40.	7040498
Öhman KP, Kågedal B, Larsson R, Karlberg BE. Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. J Cardiovasc Pharmacol (1985) 7 (Suppl 1), S20–S24.	2580171
Müller H-M, Overlack A, Heck I, Kolloch R, Stumpe KO. The influence of food intake on pharmacodynamics and plasma concentration of captopril. J Hypertens (1985) 3 (Suppl 2), S135–S136.	3910768
Salvetti A, Pedrinelli R, Magagna A, Abdel-Haq B, Graziadei L, Taddei S, Stornello M. Influence of food on acute and chronic effects of captopril in essential hypertensive patients. J Cardiovasc Pharmacol (1985) 7 (Suppl 1), S25–S29.	2580172
Mojaverian P, Rocci ML, Vlasses PH, Hoholick C, Clementi RA, Ferguson RK. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. J Pharm Sci (1986) 75, 395–7.	3014110
Swanson BN, Vlasses PH, Ferguson RK, Bergquist PA, Till AE, Irvin JD, Harris K. Influence of food on the bioavailability of enalapril. J Pharm Sci (1984) 73, 1655–7.	6097665
Massarella JW, DeFeo TM, Brown AN, Lin A, Wills RJ. The influence of food on the pharmacokinetics and ACE inhibition of cilazapril. Br J Clin Pharmacol (1989) 27, 205S–209S.	2527534
Ferry JJ, Horvath AM, Sedman AJ, Latts JR, Colburn WA. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928. J Clin Pharmacol (1987) 27, 397–9.	3693584
Grass P, Gerbeau C, Kutz K. Spirapril: pharmacokinetic properties and drug interactions. Blood Pressure (1994) 3 (Suppl 2), 7–13.	8061850
Lecocq B, Funck-Brentano C, Lecocq V, Ferry A, Gardin M-E, Devissaguet M, Jaillon P. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin Pharmacol Ther (1990) 47, 397–402.	2311339
Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit (2001) 23, 369–73.	11477318
Mattila MJ, Aranko K, Seppala T. Acute effects of buspirone and alcohol on psychomotor skills. J Clin Psychiatry (1982) 43, 56–60.	6130074
Seppälä T, Aranko K, Mattila MJ, Shrotriya RC. Effects of alcohol on buspirone and lorazepam actions. Clin Pharmacol Ther (1982) 32, 201–7.	6124334
Rush CR, Griffiths RR. Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Exp Clin Psychopharmacol (1997) 5, 28–38.	9234037
Erwin CW, Linnoila M, Hartwell J, Erwin A, Guthrie S. Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials. J Clin Psychopharmacol (1986) 6, 199–209.	3734141
Evans SM, Levin FR. The effects of alprazolam and buspirone in light and moderate female social drinkers. Behav Pharmacol (2002) 13, 427–39.	12394419
Lewis W, Schwartz L. An occupational agent (N-butyraldoxime) causing reaction to alcohol. Med Ann Dist Columbia (1956) 25, 485–90.	13358299
Franks HM, Hagedorn H, Hensley VR, Hensley WJ, Starmer GA. The effect of caffeine on human performance, alone and in combination with alcohol. Psychopharmacologia (1975) 45, 177–81.	1215448
Nuotto E, Mattila MJ, Seppälä T, Konno K. Coffee and caffeine and alcohol effects on psychomotor function. Clin Pharmacol Ther (1982) 31, 68–76.	7053307
Newman HW, Newman EJ. Failure of dexedrine and caffeine as practical antagonists of the depressant effect of ethyl alcohol in man. Q J Stud Alcohol (1956) 17, 406–10.	13359661
Oborne DJ, Rogers Y. Interactions of alcohol and caffeine on human reaction time. Aviat Space Environ Med (1983) 54, 528–34.	6882312
Azcona O, Barbanoj MJ, Torrent J, Jané F. Evaluation of the central effects of alcohol and caffeine interaction. Br J Clin Pharmacol (1995) 40, 393–400.	8554942
Marczinski CA, Fillmore MT. Dissociative antagonistic effects of caffeine on alcohol-induced impairment of behavioral control. Exp Clin Psychopharmacol (2003) 11, 228–36.	12940502
Mackay M, Tiplady B, Scholey AB. Interactions between alcohol and caffeine in relation to psychomotor speed and accuracy. Hum Psychopharmacol (2002) 17, 151–6.	12404692
Drake CL, Roehrs T, Turner L, Scofield HM, Roth T. Caffeine reversal of ethanol effects on the multiple sleep latency test, memory, and psychomotor performance. Neuropsychopharmacology (2003) 28, 371–8.	12589390
Liguori A, Robinson JH. Caffeine antagonism of alcohol-induced driving impairment. Drug Alcohol Depend (2001) 63, 123–9.	11376916
Caley MJ, Clarke RA. Cardiac arrhythmia after mushroom ingestion. BMJ (1977) 2, 1633.	589392
Broadhurst-Zingrich L. Ink caps and alcohol. BMJ (1978) 1, 511.	564228
Cochran KW, Cochran MW. Clitocybe clavipes: antabuse-like reaction to alcohol. Mycologia (1978) 70, 1124–6.	569766
Oso BA. Mushrooms and the Yoruba people of Nigeria. Mycologia (1975) 67, 311–19.	1167931
Vanhaelen M, Vanhaelen-Fastré R, Hoyois J, Mardens Y. Reinvestigation of disulfiram-like biological activity of Coprinus atramentarius (Bull.ex Fr.) Fr.extracts. J Pharm Sci (1976) 65, 1774–6.	1036443
Wier JK, Tyler VE. An investigation of Coprinus atramentarius for the presence of disulfiram. J Am Pharm Assoc (1960) 49, 426–9.	13855374
Hatfield GM, Schaumberg JP. Isolation and structural studies of coprine, the disulfiram-like constituent of Coprinus atramentarius. Lloydia (1975) 38, 489–96.	1241098
Lindberg P, Bergman R, Wickberg B. Isolation and structure of coprine, the in vivo aldehyde dehydrogenase inhibitor in Coprinus atramentarius; syntheses of coprine and related cyclopropanone derivatives. J Chem Soc (1977) (6) 684–91.	558210
Fujiyama Y, Naitoh M, Nakamura M, Minezaki K, Shigeta Y, Okubo M. [Mushroom poisoning whose symptoms were relevant to the amount of alcohol taken]. Nippon Naika Gakkai Zasshi (2002) 91, 2189–91.	12187697
Radford AP. Ink caps and mushrooms. BMJ (1978) 1, 112.	564228
Miller DS, Stirling JL, Yudkin J. Effect of ingestion of milk on concentrations of blood alcohol. Nature (1966) 212, 1051.	21090491
Fraser AG, Rosalki SB, Gamble GD, Pounder RE. Inter-individual and intra-individual variability of ethanol concentration-time profiles: comparison of ethanol ingestion before or after an evening meal. Br J Clin Pharmacol (1995) 40, 387–92.	8926537
Jones AW, Jönsson KÅ. Food-induced lowering of blood-ethanol profiles and increased rate of elimination immediately after a meal. J Forensic Sci (1994) 39, 1084–93.	8064267
Jones AW, Jönsson KÅ, Kechagias S. Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. Br J Clin Pharmacol (1997) 44, 521–6.	9431825
Ramchandani VA, Kwo PY, Li T-K. Effect of food and food composition on alcohol elimination rates in healthy men and women. J Clin Pharmacol (2001) 41, 1345–50.	11762562
Helander A, Some M. Dietary serotonin and alcohol combined may provoke adverse physiological symptoms due to 5-hydroxytryptophol. Life Sci (2000) 67, 799–806.	10968409
Benton D, Nabb S. Breakfasts that release glucose at different speeds interact with previous alcohol intake to influence cognition and mood before and after lunch. Behav Neurosci (2004) 118, 936–43.	15506876
Carai MAM, Agabio R, Bombardelli E, Bourov I, Gessa GL, Lobina C, Morazzoni P, Pani M, Reali R, Vacca G, Colombo G. Potential use of medicinal plants in the treatment of alcoholism. Fitoterapia (2000) 71 (Suppl 1), S38–S42.	10930711
Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev (1997) 16, 147–55.	16203421
Chauhan BL, Kulkarni RD. Alcohol hangover and Liv.52. Eur J Clin Pharmacol (1991) 40, 187–8.	2065699
Chauhan BL, Kulkarni RD. Effect of Liv.52, a herbal preparation, on absorption and metabolism of ethanol in humans. Eur J Clin Pharmacol (1991) 40, 189–91.	2065700
Hobbes J, Boutagy J, Shenfield GM. Interactions between ethanol and oral contraceptive steroids. Clin Pharmacol Ther (1985) 38, 371–80.	4042520
Jones MK, Jones BM. Ethanol metabolism in women taking oral contraceptives. Alcohol Clin Exp Res (1984) 8, 24–8.	6741669
Zeiner AR, Kegg PS. Menstrual cycle and oral contraceptive effects on alcohol pharmacokinetics in caucasian females. Curr Alcohol (1981) 8, 47–56.	7343191
Sarkola T, Ahola L, von der Pahlen B, Eriksson CJP. Lack of effect of alcohol on ethinylestradiol in premenopausal women. Contraception (2001) 63, 19–23.	11257244
Lee A, Chui PT, Aun CST, Gin T, Lau ASC. Possible interaction between sevoflurane and aloe vera. Ann Pharmacother (2004) 38, 1651–4.	15292490
Anon. Piper methysticum (kava kava). Altern Med Rev (1998) 3, 458–60.3. Pepping J. Kava: Piper methysticum. Am J Health-Syst Pharm (1999) 56, 957–8 and 960	10578942
Larkin, M. Surgery patients at risk for herb–anaesthesia interactions. Lancet (1999) 354, 1362.	10533874
Cheng B, Hung CT, Chiu W. Herbal medicine and anaesthesia. Hong Kong Med J (2002) 8, 123–30.	14567065
Leak JA. Perioperative considerations in the management of the patient taking herbal medicines. Curr Opin Anaesthesiol (2000) 13, 321–5.	17016323
Lyons TR. Herbal medicines and possible anesthesia interactions. AANA J (2002) 70, 47–51.	12393786
Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health-Syst Pharm (1999) 56, 125–38.	10030529
Miller LG. Herbal medicinals. Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med (1998) 158, 2200–11.	11365266
Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St John’s wort. J Clin Anesth (2000) 12, 498–9.	11203429
Stempak D, Gammon J, Halton J, Champagne M, Koren G, Baruchel S. Modulation of celecoxib pharmacokinetics by food in pediatric patients. Clin Pharmacol Ther (2005) 77, 226–8.	15735617
Poli A, Moreno RA, Ribiero W, Dias HB, Moreno H, Muscara MN, De Nucci G. Influence of gastric acid secretion blockade and food intake on the bioavailability of a potassium diclofenac suspension in healthy male volunteers. Int J Clin Pharmacol Ther (1996) 34, 76–9.	8929750
McEwen J, De Luca M, Casini A, Gich I, Barbanoj MJ, Tost D, Artigas R, Mauleón D. The effect of food and an antacid on the bioavailability of dexketoprofen trometamol. J Clin Pharmacol (1998) 38 (Suppl), 41S–45S.	9882081
Pargal A, Kelkar MG, Nayak PJ. The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulation. Biopharm Drug Dispos (1996) 17, 511–19.	8866042
Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther (2006) 79, 125–33.	16413247
Siemon D, de Vries JX, Stötzer F, Walter-Sack I, Dietl R. Fasting and postprandial disposition of R(-)- and S(+)-ibuprofen following oral administration of racemic drug in healthy individuals. Eur J Med Res (1997) 2, 215–19.	9153347
Klueglich M, Ring A, Scheuerer S, Trommeshauser D, Schuijt C, Liepold B, Berndl G. Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all formulations. J Clin Pharmacol (2005) 45, 1055–61.	16100300
Caillé G, du Souich P, Besner JG, Gervais P, Vèzina M. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med (1989) 86 (Suppl 6A) 38–44. Correction. ibid. (1990) 89, 838.	2735334
Bannwarth B, Lapicque F, Netter P, Monot C, Tamisier JN, Thomas P, Royer RJ. The effect of food on the systemic availability of ketoprofen. Eur J Clin Pharmacol (1988) 33, 643–5.	3366169
Le Liboux A, Teule M, Frydman A, Oosterhuis B, Jonkman JHG. Effect of diet on the single- and multiple-dose pharmacokinetics of sustained-release ketoprofen. Eur J Clin Pharmacol (1994) 47, 361–6.	7875189
Mroszczak E, Yee JP, Bynum L. Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. J Clin Pharmacol (1988) 28, 1128–31.	3243931
Palazzini E, Cristofori M, Babbini M. Bioavailability of a new controlled-release oral naproxen formulation given with and without food. Int J Clin Pharmacol Res (1992) 12, 179–84.	1297641
Forbes JA, Sandberg RÅ, Bood-Björklund L. The effect of food on bromfenac, naproxen sodium, and acetaminophen in postoperative pain after orthopedic surgery. Pharmacotherapy (1998) 18, 492–503.	9620100
Marzo A, Dal Bo L, Wool C, Cerutti R. Bioavailability, food effect and tolerability of S-naproxen betainate sodium salt monohydrate in steady state. Arzneimittelforschung (1998) 48, 935–40.	9793622
Emori HW, Paulus H, Bluestone R, Champion GD, Pearson C. Indomethacin serum concentrations in man. Effects of dosage, food, and antacid. Ann Rheum Dis (1976) 35, 333–8.	970990
von Schrader HW, Buscher G, Dierdorf D, Mügge H, Wolf D. Nabumetone — a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Int J Clin Pharmacol Ther Toxicol (1983) 21, 311–21.	6688407
Ishizaki T, Nomura T, Abe T. Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. J Pharmacokinet Biopharm (1979) 7, 369–81.	512843
Tilstone WJ, Lawson DH, Omara F, Cunningham F. The steady-state pharmacokinetics of piroxicam: effect of food and iron. Eur J Rheumatol Inflamm (1981) 4, 309–13.	6242951
Day RO, Lam S, Paull P, Wade D. Effect of food and various antacids on the absorption of tenoxicam. Br J Clin Pharmacol (1987) 24, 323–8.	3499163
Busch U, Heinzel G, Narjes H. Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID). Agents Actions (1991) 32, 52–3.	2058471
Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis (2003) 167, 367.	12818420
Hoffman T. Ginko, Vioxx and excessive bleeding – possible drug-herb interactions: case report. Hawaii Med J (2001) 60, 290.	11797495
Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A, Reynolds RC, Harmatz JS, Avula B, Khan IA, Goldman P. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol (2006) 46, 214–21.	17641611
Mohutsky MA, Anderson GD, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther (2006) 13, 24–31.	16428919
Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology (1996) 46, 1775–6.	8649594
Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet (1998) 352, 36.	9800751
Gilbert GJ. Ginkgo biloba. Neurology (1997) 48, 1137.	15344253
Benjamin J, Muir T, Briggs K, Pentland B. A case of cerebral haemorrhage – can Ginkgo biloba be implicated? Postgrad Med J (2001) 77, 112–13.	11161079
Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg (2001) 67, 33–5.	11206893
Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology (2004) 101, 729–37.	15329598
Benmebarek M, Devaud C, Gex-Fabry M, Powell Golay K, Brogli C, Baumann P, Gravier B, Eap CB. Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clin Pharmacol Ther (2004) 76, 55–63.	15229464
Van Thuyne W, Van Eenoo P, Delbeke FT. Urinary concentrations of morphine after the administration of herbal teas containing Papaveris fructus in relation to doping analysis. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 785, 245–51.	12554137
Eic-Höchli D, Oppliger R, Powell Golay K, Baumann P, Eap CB. Methadone maintenance treatment and St John’s wort. Pharmacopsychiatry (2003) 36, 35–7.	12649774
Kumar NB, Allen K, Bel H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control (2005) 12, 149–57.	16062162
Robertson DRC, Higginson I, Macklin BS, Renwick AG, Waller DG, George CF. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol (1991) 31, 413–17.	2049250
Wessels JC, Koeleman HA, Boneschans B, Steyn HS. The influence of different types of breakfast on the absorption of paracetamol among members of an ethnic group. Int J Clin Pharmacol Ther Toxicol (1992) 30, 208–13.	1612815
Walter-Sack IE, de Vries JX, Nickel B, Stenzhorn G, Weber E. The influence of different formula diets and different pharmaceutical formulations on the systemic availability of paracetamol, gallbladder size, and plasma glucose. Int J Clin Pharmacol Ther Toxicol (1989) 27, 544–50.	2613389
Holt S, Heading RC, Carter DC, Prescott LF, Tothill P. Effect of gel fibre on gastric emptying and absorption of glucose and paracetamol. Lancet (1979) 1, 636–9.	85872
Forbes JA, Sandberg RA, Bood-Bjorklund L. The effect of food on bromfenac, naproxen sodium, and acetaminophen in postoperative pain after orthopedic surgery. Pharmacotherapy (1998) 18, 492–503.	9620100
Burnett I, Schachtel B, Sanner K, Bey M, Grattan T, Littlejohn S. Onset of analgesia of a paracetamol tablet containing sodium bicarbonate: a double-blind, placebo-controlled study in adult patients with acute sore throat. Clin Ther (2006) 28, 1273–8.	17062300
Prescott LF, Yoovathaworn K, Makarananda K, Saivises R, Sriwatanakul K. Impaired absorption of paracetamol in vegetarians. Br J Clin Pharmacol (1993) 36, 237–40.	9114910
Stillings M, Havlik I, Chetty M, Clinton C, Schall R, Moodley I, Muir N, Little S. Comparison of the pharmacokinetic profiles of soluble aspirin and solid paracetamol tablets in fed and fasted volunteers. Curr Med Res Opin (2000) 16, 115–24.	10893655
Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA (1994) 272, 1845–50.	7990219
Schenker S, Speeg KV, Perez A, Finch J. The effects of food restriction in man on hepatic metabolism of acetaminophen. Clin Nutr (2001) 20, 145–50.	11327742
Pantuck EJ, Pantuck CB, Anderson KE, Wattenberg LW, Conney AH, Kappas A. Effect of brussels sprouts and cabbage on drug conjugation. Clin Pharmacol Ther (1984) 35, 161–9.	6692645
Chen L, Mohr SN, Yang CS. Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers. Clin Pharmacol Ther (1996) 60, 651–60.	8988067
Anderson KE, Schneider J, Pantuck EJ, Pantuck CB, Mudge GH, Welch RM, Conney AH, Kappas A. Acetaminophen metabolism in subjects fed charcoal-broiled beef. Clin Pharmacol Ther (1983) 34, 369–74.	6883912
Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev (1994) 3, 155–60.	8049637
Kolawole JA, Maduenyi A. Effect of Zobo drink (Hibiscus sabdariffa water extract) on the pharmacokinetics of acetaminophen in human volunteers. Eur J Drug Metab Pharmacokinet (2004) 29, 25–9.	15151167
Qi J, Toyoshima A, Honda Y, Mineshita S. Pharmacokinetic study on acetaminophen: interaction with a Chinese medicine. J Med Dent Sci (1997) 44, 31–5.	9385040
Homeida M, Leahy W, Copeland S, Ali MMM, Harron DWG. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol (1994) 88, 551–9.	7979646
Nagy J, Schipper HG, Koopmans RP, Butter JJ, Van Boxtel CJ, Kager PA. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg (2002) 66, 260–3.	12495014
Feeley J, Heidemann H, Gerkens J, Roberts LJ, Branch RA. Sodium depletion enhances nephrotoxicity of amphotericin B. Lancet (1981) i, 1422–3.	6113376
Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med (1983) 75, 476–81.	6614033
Dixon R, Pozniak AL, Watt HM, Rolan P, Posner J. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother (1996) 40, 556–60.	8851570
Falloon J, Sargent S, Piscitelli SC, Bechtel C, LaFon SW, Sadler B, Walker RE, Kovacs JA, Polis MA, Davey RT, Lan HC, Masur H. Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. Pharmacotherapy (1999) 19, 1050–6.	10610011
Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH. Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother (1998) 32, 1004–7.	9793589
Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol (1994) 37, 13–20.	8148213
Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on absorption of itraconazole. Eur J Clin Pharmacol (1997) 52, 235–7.	9218932
Chin TWF, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother (1995) 39, 1671–5.	7486898
Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol (1994) 46, 147–150.	8039534
Wishart JM. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J Am Acad Dermatol (1987) 17, 220–3.	3040815
Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van De Velde V. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother (1993) 37, 778–.	8388198
Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy (1998) 18, 295–301.	9545149
Männistö PT, Mäntylä R, Nykänen S, Lamminsivu U, Ottoila P. Impairing effect of food on ketoconazole absorption. Antimicrob Agents Chemother (1982) 21, 730–33.	6285814
Lelawongs P, Barone JA, Colaizzi JL, Hsuan ATM, Mechlinski W, Legendre R, Guarnieri J. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm (1988) 7, 228–35.	3356120
Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, Williamson PJ. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother (1984) 25, 1–3.	6322675
Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol (2003) 56 (Suppl 1) 17–23.	14616409
Penzak SR, Gubbins PO, Gurley BJ, Wang P-L, Saccente M. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit (1999) 21, 304–309.	10365642
Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakumara H. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther (1998) 36, 306–308.	9660036
Gubbins PO, McConnell SA, Gurley BJ, Fincher TK, Franks AM, Williams DK, Penzak SR, Saccente M. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. Pharmacotherapy (2004) 24, 460–7.	15098799
Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (Benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 44, 697–704.	10681341
van Agtmael MA, Gupta V, van der Wosten TH, Rutten JP, van Boxtel CJ. Grapefruit juice increases the bioavailability of artemether. Eur J Clin Pharmacol (1999) 55, 405–10.	10456492
van Agtmael MA, Gupta V, van der Graaf CAA, van Boxtel CJ. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther (1999) 66, 408–14.	10546925
Castro N, Jung H, Medina R, González-Esquivel D, Lopez M, Sotelo J. Interaction between grapefruit juice and praziquantel in humans. Antimicrob Agents Chemother (2002) 46, 1614–16.	11959616
Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S. Grapefruit juice has no effect on quinine pharmacokinetics. Eur J Clin Pharmacol (1999) 55, 393–8.	10456490
Libersa CC, Brique SA, Motte KB, Caron JF, Guédon-Moreau LM, Humbert L, Vincent A, Devos P, Lhermitte MA. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol (2000) 49, 373–8.	10759694
Min DI, Ku Y-M, Geraets DR, Lee H-C. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol (1996) 36, 469–76.	8739026
Damkier P, Hansen LL, Brøsen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol (1999) 48, 829–38.	10594487
Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy (2001) 21, 891–7.	11718495
Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother (1999) 43, 568–72.	10460103
Peloquin CA, Namdar S, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis (1999) 3, 703–710.	10460103
Männisto P, Mäntylä R, Klinge R, Nykänen S, Koponen A, Lamminsivu U. Influence of various diets on the bioavailability of isoniazid. J Antimicrob Chemother (1982) 10, 427–34.	7174567
Smith CK, Durack DT. Isoniazid and reaction to cheese. Ann Intern Med (1978) 88, 520–1.	637437
Lejonc JL, Gusmini D, Brochard P. Isoniazid and reaction to cheese. Ann Intern Med (1979) 91, 793.	496127
Hauser MJ, Baier H. Interactions of isoniazid with foods. Drug Intell Clin Pharm (1982) 16, 617–18.	7105982
Carvalho ACC, Manfrin M, Gore RP, Capone S, Scalvini A, Armellini A, Giovine T, Carosi G, Matteelli A. Reaction to cheese during TB treatment. Thorax (2004) 59, 635.	15223879
Uragoda CG, Kottegoda SR. Adverse reactions to isoniazid on ingestion of fish with a high histamine content. Tubercle (1977) 58, 83–9.	406701
Uragoda CG. Histamine poisoning in tuberculous patients after ingestion of tuna fish. Am Rev Respir Dis (1980) 121, 157–9.	7188722
Uragoda CG. Histamine poisoning in tuberculous patients on ingestion of tropical fish. J Trop Med Hyg (1978) 81, 243–5.	571023
O’Sullivan TL. Drug-food interaction with isoniazid resembling anaphylaxis. Ann Pharmacother (1997) 31, 928–9.	9220063
Welshman IR, Sisson TA, Jungbluth GL, Stalker D, Hopkins NK. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos (2001) 22, 91–7.	11745911
Islinger F, Dehghanyar P, Sauermann R, Burger C, Kloft C, Muller M, Joukhader C. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents (2006) 27, 108–12.	16388930
Antal EJ, Hendershot PE, Batts DH, Sheu W-P, Hopkins NK, Donaldson KM. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol (2001) 41, 552–62.	11361052
Cantarini MV, Painter CJ, Gilmore EM, Bolger C, Watkins CL, Hughes AM. Effect of oral linezolid on the pressor response to intravenous tyramine. Br J Clin Pharmacol (2004) 58, 470–5.	15521893
Roller S, Lode H, Stelzer I, Deppermann KM, Boeckh M, Koeppe P. Pharmacokinetics of loracarbef and interaction with acetylcysteine. Eur J Clin Microbiol Infect Dis (1992) 11, 851–5.	1468429
DeSante KA, Zeckel ML. Pharmacokinetic profile of loracarbef. Am J Med (1992) 92 (Suppl 6A), 16S–19S.	1621740
Lutz M, Espinoza J, Arancibia A, Araya M, Pacheco I, Brunser O. Effect of structured dietary fiber on bioavailability of amoxicillin. Clin Pharmacol Ther (1987) 42, 220–4.	3038451
Koo WWK, Ke J, Tam YK, Finegan BA, Marriage B. Pharmacokinetics of ampicillin during parenteral nutrition. J Parenter Enteral Nutr (1990) 14, 279–82.	2112643
Welling PG, Huang H, Koch PA, Craig WA, Madsen PO. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. J Pharm Sci (1977) 66, 549–52.	323461
Eshelman FN, Spyker DA. Pharmacokinetics of amoxicillin and ampicillin: crossover study of the effect of food. Antimicrob Agents Chemother (1978) 14, 539–43.	363052
Staniforth DH, Lillystone RJ, Jackson D. Effect of food on the bioavailability and tolerance of clavulanic acid/amoxycillin combination. J Antimicrob Chemother (1982) 10, 131–9.	7118763
Neuvonen PJ, Elonen E, Pentikainen PJ. Comparative effect of food on absorption of ampicillin and pivampicillin. J Int Med Res (1977) 5, 71–6.	838114
Sommers DK, van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol (1984) 18, 535–9.	6091711
Babalola CP, Iwheye GB, Olaniyi AA. Effect of proguanil interaction on bioavailability of cloxacillin. J Clin Pharm Ther (2002) 27, 461–4.	12472986
McCracken GH, Ginsburg CM, Clahsen JC, Thomas ML. Pharmacologic evaluation of orally administered antibiotics in infants and children: effect of feeding on bioavailability. Pediatrics (1978) 62, 738–43.	581516
Staniforth DH, Clarke HL, Horton R, Jackson D, Lau D. Augmentin bioavailability following cimetidine, aluminium hydroxide and milk. Int J Clin Pharmacol Ther Toxicol (1985) 23, 154–7.	3838971
Hasegawa T, Yamaki K, Nadai M, Muraoka I, Wang L, Takagi K, Nabeshima T. Lack of effect of Chinese medicines on bioavailability of ofloxacin in healthy volunteers. Int J Clin Pharmacol Ther (1994) 32, 57–61.	8004359
Hasegawa T, Yamaki K-I, Muraoka I, Nadai M, Takagi K, Nabeshima T. Effects of traditional Chinese medicines on pharmacokinetics of levofloxacin. Antimicrob Agents Chemother (1995) 39, 2135–7.	8540731
Neuvonen PJ, Kivistö KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther (1991) 50, 498–502.	1934862
Hoogkamer JFW, Kleinbloesem CH. The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers. Drugs (1995) 49 (Suppl 2), 346–8.	8549357
Lehto P, Kivistö KT. Effects of milk and food on the absorption of enoxacin. Br J Clin Pharmacol (1995) 39, 194–6.	7742162
Lehto PL, Kivistö KT. Different effects of products containing metal ions on the absorption of lomefloxacin. Clin Pharmacol Ther (1994) 56, 477–82.	7955811
Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet (2001) 40 (Suppl 1) 33–8.	11352440
Kivistö KT, Ojala-Karlsson P, Neuvonen PJ. Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother (1992) 36, 489–91.	1605619
Dudley MN, Marchbanks CR, Flor SC, Beals B. The effect of food or milk on the absorption kinetics of ofloxacin. Eur J Clin Pharmacol (1991) 41, 569–71.	1797525
Neuvonen PJ, Kivistö KT. Milk and yoghurt do not impair the absorption of ofloxacin. Br J Clin Pharmacol (1992) 33, 346–8.	1476449
Mueller BA, Brierton DG, Abel SR, Bowman L. Effect of enteral feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother (1994) 38, 2101–5.	7811026
Piccolo ML, Toossi Z, Goldman M. Effect of coadministration of a nutritional supplement on ciprofloxacin absorption. Am J Hosp Pharm (1994) 51, 2697–9.	7856583
Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother (1996) 40, 6–10.	8787869
Yuk JH, Nightingale CH, Quintiliani R, Yeston NS, Orlando R, Dobkin ED, Kambe JC, Sweeney KR, Buonpane EA. Absorption of ciprofloxacin administered through a nasogastric tube or a nasoduodenal tube in volunteers and patients receiving enteral nutrition. Diagn Microbiol Infect Dis (1990) 13, 99–102.	2114955
Yuk JH, Nightingale CH, Sweeney KR, Quintiliani R, Lettieri JT, Frost RW. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding. Antimicrob Agents Chemother (1989) 33, 1118–20.	2506806
de Marie S, VandenBergh MFQ, Buijk SLCE, Bruining H, van Vliet A, Kluytmans JAJW, Mouton JW. Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections. Intensive Care Med (1998) 24, 343–6.	9609412
Mimoz O, Binter V, Jacolot A, Edouard A, Tod M, Petitjean O, Samii K. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med (1998) 24, 1047–51.	9840238
Wright DH, Pietz SL, Konstantinides FN, Rotschafer JC. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. J Parenter Enteral Nutr (2000) 24, 42–8.	10638471
Burkhardt O, Stass H, Thuss U, Borner K, Welte T. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Clin Pharmacokinet (2005) 44, 969–76.	16122283
Frost RW, Carlson JD, Dietz AJ, Heyd A, Lettieri JT. Ciprofloxacin pharmacokinetics after a standard or high-fat/high-calcium breakfast. J Clin Pharmacol (1989) 29, 953–5.	2589383
Verho M, Malerczyk V, Dagrosa E, Korn A. The effect of food on the pharmacokinetics of ofloxacin. Curr Med Res Opin (1986) 10, 166–71.	3460737
Dudley MN, Marchbanks CR, Flor SC, Beals B. The effect of food or milk on the absorption kinetics of ofloxacin. Eur J Clin Pharmacol (1991) 41, 569–71.	1797525
Hooper WD, Dickinson RG, Eadie MJ. Effect of food on absorption of lomefloxacin. Antimicrob Agents Chemother (1990) 34, 1797–9.	2285293
Somogyi AA, Bochner F, Keal JA, Rolan PE, Smith M. Effect of food on enoxacin absorption. Antimicrob Agents Chemother (1987) 31, 638–9.	3475034
Allen A, Bygate E, Clark D, Lewis A, Pay V. The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents (2000) 16, 45–50.	11185412
Johnson RD, Dorr MB, Hunt TL, Jensen BK, Talbot GH. Effects of food on the pharmacokinetics of sparfloxacin. Clin Ther (1999) 21, 982–91.	10440622
Neuhofel AL, Wilton JH, Victory JM, Hejmanowski LG, Amsden GW. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol (2002) 42, 461–6.	11936572
Wallace AW, Victory JM, Amsden GW. Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers. J Clin Pharmacol (2003) 43, 92–6.	12520633
Wallace AW, Victory JM, Amsden GW. Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers. J Clin Pharmacol (2003) 43, 539–44.	12971031
Amsden GW, Whitaker A-M. Johnson PW. Lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal. J Clin Pharmacol (2003) 43, 990–95.	12971031
Cohn SM, Sawyer MD, Burns GA, Tolomeo C, Milner KA. Enteric absorption of ciprofloxacin during tube feeding in the critically ill. J Antimicrob Chemother (1996) 38, 871–6.	8961058
Scheiner J, Altemeier WA. Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. Surg Gynecol Obstet (1962) 114, 9–14.	14498173
Rosenblatt JE, Barrett JE, Brodie JL, Kirby WMM. Comparison of in vitro activity and clinical pharmacology of doxycycline with other tetracyclines. Antimicrob Agents Chemother (1966) 6, 134–41.	4964450
Meyer FP, Specht H, Quednow B, Walther H. Influence of milk on bioavailability of doxycycline — new aspects. Infection (1989) 17, 245–6.	2767766
Saux M-C, Mosser J, Pontagnier H, Leng B. Pharmacokinetic study of doxycycline polyphosphate after simultaneous ingestion of milk. Eur J Drug Metab Pharmacokinet (1983) 8, 43–9.	6688049
Leyden JJ. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. J Am Acad Dermatol (1985) 12, 308–12.	3838321
Jung H, Rivera O, Reguero MT, Rodríguez JM, Moreno-Esparza R. Influence of liquids (coffee and orange juice) on the bioavailability of tetracycline. Biopharm Drug Dispos (1990) 11, 729–34.	2271748
Cook HJ, Mundo CR, Fonseca L, Gasque L, Moreno-Esparza R. Influence of the diet on bioavailability of tetracycline. Biopharm Drug Dispos (1993) 14, 549–53.	8218972
Albert A, Rees CW. Avidity of the tetracyclines for the cations of metals. Nature (1956) 177, 433–4.	13309332
Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. BMJ (2003) 327, 1454.	14684645
Grant P. Warfarin and cranberry juice: an interaction? J Heart Valve Dis (2004) 13, 25–6.	14765835
Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. Am J Ther (2006) 13, 283–4.	16772772
Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther (2006) 79, 125–33.	16413247
Melander A, Wåhlin E. Enhancement of dicoumarol bioavailability by concomitant food intake. Eur J Clin Pharmacol (1978) 14, 441–4.	83942
O’Reilly RA, Rytand DA. ‘Resistance’ to warfarin due to unrecognized vitamin K supplementation. N Engl J Med (1980) 303, 160–1.	7383081
Westfall LK. An unrecognized cause of warfarin resistance. Drug Intell Clin Pharm (1981) 15, 131.	7274023
Lader EW, Yang L, Clarke A. Warfarin dosage and vitamin K in Osmolite. Ann Intern Med (1980) 93, 373–4.	7406391
Lee M, Schwartz RN, Sharifi R. Warfarin resistance and vitamin K. Ann Intern Med (1981) 94, 140–1.	7312071
Zallman JA, Lee DP, Jeffrey PL. Liquid nutrition as a cause of warfarin resistance. Am J Hosp Pharm (1981) 38, 1174.	7270565
Parr MD, Record KE, Griffith GL, Zeok JV, Todd EP. Effect of enteral nutrition on warfarin therapy. Clin Pharm (1982) 1, 274–6.	6821036
Kutsop JJ. Update on vitamin K 1 content of enteral products. Am J Hosp Pharm (1984) 41, 1762.	6437219
Howard PA, Hannaman KN. Warfarin resistance linked to enteral nutrition products. J Am Diet Assoc (1985) 85, 713–15.	3998343
Martin JE, Lutomski DM. Warfarin resistance and enteral feedings. J Parenter Enteral Nutr (1989) 13, 206–8.	2496251
Petretich DA. Reversal of Osmolite-warfarin interaction by changing warfarin administration time. Clin Pharm (1990) 9, 93.	2106407
Watson AJM, Pegg M, Green JRB. Enteral feeds may antagonise warfarin. BMJ (1984) 288, 557.	6421377
Oren B, Shvartzman P. Unsuspected source of vitamin K in patients treated with anticoagulants: a case report. Fam Pract (1989) 6, 151–2.	2663579
Streif W, Marzinotto AV, Massicotte P, Chan AKC, Julian JA, Mitchell L. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood (1999) 94, 3007–14.	10556183
Lutomski DM, Palascak JE, Bower RH. Warfarin resistance associated with intravenous lipid administration. J Parenter Enteral Nutr (1987) 11, 316–18.	3110450
MacLaren R, Wachsman BA, Swift DK, Kuhl DA. Warfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature. Pharmacotherapy (1997) 17, 1331–7.	9399621
Helphingstine CJ, Bistrian BR. New Food and Drug Administration requirements for inclusion of vitamin K in adult parenteral multivitamins. J Parenter Enteral Nutr (2003) 27, 220–4.	12757117
Monterrey-Rodríguez J, Feliú JF, Rivera-Miranda GC. Interaction between warfarin and mango fruit. Ann Pharmacother (2002) 36, 940–1.	12014354
Kudo T. Warfarin antagonism of natto and increase in serum vitamin K by intake of natto. Artery (1990) 17, 189–201.	2360879
Cambria-Kiely JA. Effect of soy milk on warfarin efficacy. Ann Pharmacother (2002) 36, 1893–6.	12452752
Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis (2000) 30, 298–307.	11356998
Blickstein D, Shaklai M, Inbal A. Warfarin antagonism by avocado. Lancet (1991) 337, 914–15.	1672990
Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother (1999) 33, 426–8.	10332534
Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther (2006) 79, 125–33.	16413247
Pedersen FM, Hamberg O, Hess K, Ovesen L. The effect of dietary vitamin K on warfarin-induced anticoagulation. J Intern Med (1991) 229, 517–20.	2045759
Udall JA, Krock LB. A modified method of anticoagulant therapy. Curr Ther Res (1968) 10, 207–11.	4967225
Udall JA. Human sources and absorption of vitamin K in relation to anticoagulation stability. JAMA (1965) 194, 127–9.	5897315
Qureshi GD, Reinders P, Swint JJ, Slate MB. Acquired warfarin resistance and weight-reducing diet. Arch Intern Med (1981) 141, 507–9.	7212893
Kempin SJ. Warfarin resistance caused by broccoli. N Engl J Med (1983) 308, 1229–30.	6843604
Chow WH, Chow TC, Tse TM, Tai YT, Lee WT. Anticoagulation instability with life-threatening complication after dietary modification. Postgrad Med J (1990) 66, 855–7.	2099431
Walker FB. Myocardial infarction after diet-induced warfarin resistance. Arch Intern Med (1984) 144, 2089–90.	6486994
Karlson B, Leijd B, Hellström A. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. Acta Med Scand (1986) 220, 347–50.	3541503
Schurgers LJ, Shearer MJ, HamulyáK K, Stöcklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood (2004) 104, 2682–9.	15231565
Kalra PA, Cooklin M, Wood G, O’Shea GM, Holmes AM. Dietary modification as a cause of anticoagulation instability. Lancet (1988) ii, 803.	2901653
Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. J Nutr (1996) 126, 1181S–1186S.	8642453
Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis (2000) 30, 298–307.	11356998
Bartle WR, Madorin P, Ferland G. Seaweed, vitamin K, and warfarin. Am J Health-Syst Pharm (2001) 58, 2300.	11763808
Flannery EP, MacDonald BS, O’Leary DS, McGinty JM. Japanese-restaurant syndrome. N Engl J Med (1971) 285, 414.	5104893
Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost (1999) 81, 396–9.	10102468
Couris R, Tataronis G, McCloskey W, Oertel L, Dallal G, Dwyer J, Blumberg JB. Dietary vitamin K variability affects International normalized ratio (INR) coagulation indices. Int J Vitam Nutr Res (2006) 76, 65–74.	16941417
Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, Kesteven P, Kamali F. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol (2004) 124, 348–54.	14717783
Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med (2004) 116, 651–6.	15121490
Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost (2005) 93, 872–5.	15886802
Sorano GG, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis (1993) 23, 77–82.	8365689
Gijsbers BLMG, Jie K-SG, Vermeer C. Effect of food composition on vitamin K absorption in human volunteers. Br J Nutr (1996) 76, 223–9.	8813897
Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K. J Nutr (1998) 128, 785–8.	9566982
Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. Nutr Rev (1999) 57, 288–96.	10568341
Couris RR, Tataronis GR, Booth SL, Dallal GE, Blumberg JB, Dwyer JT. Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K. J Am Coll Nutr (2000) 19, 801–6.	11194535
Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. Am J Health-Syst Pharm (1998) 55, 1581–3.	9706183
Bartle WR. Grapefruit juice might still be factor in warfarin response. Am J Health-Syst Pharm (1999) 56, 676.	10423213
Yue, Q-Y, Jansson K. Herbal drug Curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. J Am Geriatr Soc (2001) 49, 838.	11454132
Yu CM, Chan JCN, Sanderson JE. Chinese herbs and warfarin potentiation by ‘Danshen’. J Intern Med (1997) 241, 337–9.	9159606
Izzat MB, Yim APC, El-Zufari MH. A taste of Chinese medicine. Ann Thorac Surg (1998) 66, 941–2.	9768962
Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H, Niihara Y. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr (2006) 136 (3 Suppl), 793S–795S.	16484565
German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. Br J Urol (1995) 76, 518.	7551902
Rose KD, Croissant PD, Parliament CF, Levin MP. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery (1990) 26, 880–2.	2352608
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 59, 425–32.	15801937
Krüth P, Brosi E, Fux R, Mörike K, Gleiter CH. Ginger-associated overanticoagulation by phenprocoumon. Ann Pharmacother (2004) 38, 257–60.	14742762
Lesho EP, Saullo L, Udvari-Nagy S. A 76-year-old woman with erratic anticoagulation. Cleve Clin J Med (2004) 71, 651–6 .	15449760
Braun L. Herb-drug interaction guide. Aust Fam Physician (2001) 30, 473–6.	11558205
Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother (2000) 34, 1478–82.	11144706
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 59, 425–32.	15801937
Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology (1998) 50, 1933.	9633781
Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother (2000) 34, 1478–82.	11144706
Mohutsky MA, Anderson GA, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther (2006) 13, 24–31.	16428919
Yuan C-S, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. Brief communication: American ginseng reduces warfarin’s effect in healthy patients. Ann Intern Med (2004) 141, 23–27. Importance and management.	15238367
Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health-Syst Pharm (1997) 54, 692–3.	9075501
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 57, 592–99.	15089812
Hogan RP. Hemorrhagic diathesis caused by drinking an herbal tea. JAMA (1983) 249, 2679–80.	6133016
Plotnikoff GA, McKenna D, Watanabe K, Blumenthal M. Ginseng and warfarin interactions. Ann Intern Med (2004) 141, 893–4.	15655860
Zhu M, Chan KW, Ng LS, Chang Q, Chang S, Li RC. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol (1999) 51, 175–80.	10217316
Hopkins MP, Androff L, Benninghoff AS. Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol (1988) 159, 1121–2.	3189445
Greenspan EM. Ginseng and vaginal bleeding. JAMA (1983) 249, 2018.	6834589
Kuo S-C, Teng C-M, Leed J-C, Ko F-N, Chen S-C, Wu T-S. Antiplatelet components in Panax ginseng. Planta Med (1990) 56, 164–7.	2353062
Lam AY, Elmer GW, Mohutsky M. Possible interaction between warfarin and Lycium barbarum. Ann Pharmacother (2001) 35, 1199–1201.	11675844
Wong ALN, Chan TYK. Interaction between warfarin and the herbal product quilinggao. Ann Pharmacother (2003) 37, 836–8.	12773074
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 57, 592–9.	15089812
Yue Q-Y, Bergquist C, Gerdén B. Safety of St John’s wort (Hypericum perforatum). Lancet (2000) 355, 576–7.	11276296
Carr ME, Klotz J, Bergeron M. Coumadin resistance and the vitamin supplement “Noni”. Am J Hematol (2004) 77, 103–4.	15307118
Pirk LA, Engelberg R. Hypoprothrombinemic action of quinine sulfate. Am J Med Sci (1947) 213, 593–7.	20238900
Quick AJ. Effect of synthetic vitamin K and quinine sulfate on the prothrombin level. J Lab Clin Med (1946) 31, 79–84.	21010059
Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet (1979) i, 607.	85186
Leatherdale BA, Panesar KR, Singh G, Atkins TW, Bailey CJ, Bignell AHC. Improvement in glucose tolerance due to Momordica charantia (karela). BMJ (1981) 282, 1823–4.	6786635
Tongia A, Tongia SK, Dave M. Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). Indian J Physiol Pharmacol (2004) 48, 241–44.	15521566
Welihinda J, Karunanayake EH, Sheriff MHR, Jaysinghe KSA . Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol (1986) 17, 277–82.	3807390
Akhtar MS. Trial of Momordica Charantia Linn (Karela) powder in patients with maturity-onset diabetes. J Pakistan Med Assoc (1982) 32, 106–7.	6806502
Wang Z, Gorski JC, Hamman MA, Huang S-M, Lesko LJ, Hall SD. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther (2001) 70, 317–26.	11871046
Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin H-H, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med (2005) 71, 331–7.	15856409
Ohnishi N, Nakasako S, Okada K, Umehara S, Takara K, Nagasawa K, Yoshioka M, Kuroda K, Yokoyama T. Studies on interactions between traditional herbal and Western medicines. IV: Lack of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to and carbamazepine in rats. Eur J Drug Metab Pharmacokinet (2001) 26, 129–35.	11554427
Ohnishi N, Yonekawa Y, Nakasako S, Nagasawa K, Yokoyama T, Yoshioka M, Kuroda K. Studies on interactions between traditional herbal and Western medicines. I.Effects of Sho-seiryu-to on the pharmacokinetics of carbamazepine in rats. Biol Pharm Bull (1999) 22, 527–31.	10375176
Lau KK, Lai CK, Chan AYM. Phenytoin poisoning after using Chinese proprietary medicines. Hum Exp Toxicol (2000) 19, 385–6.	11002387
Bonin B, Vandel P, Vandel S, Kantelip JP. Effect of grapefruit intake on carbamazepine bioavailability: a case report. Therapie (2001) 56, 69–71.	11322025
Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther (1998) 64, 286–8.	9757152
Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet (1997) 33, 103–21.	9555149
Hidaka M, Okumura M, Fujita K-I, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K. Effects of pomegranate juice on human cytochrome P450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos (2005) 33, 644–8.	15673597
Gidal BE, Maly MM, Budde J, Lensmeyer GL, Pitterle ME, Jones JC. Effect of a high-protein meal on gabapentin pharmacokinetics. Epilepsy Res (1996) 23, 71–6.	8925804
Gidal BE, Maly MM, Kowalski JW, Rutecki PA, Pitterle ME, Cook DE. Gabapentin absorption: effect of mixing with foods of varying macronutrient composition. Ann Pharmacother (1998) 32, 405–9.	9562133
Parnell J, Sheth R, Limdi N, Gidal BE. Oral absorption of gabapentin syrup is not impaired by concomitant administration with various beverages or enteral nutrition supplement. Epilepsia (2001) 42 (Suppl 7), 91.	11906584
Johansson Ö, Wahlin-Boll E, Lindberg T, Melander A. Opposite effects of carbohydrate and protein on phenytoin absorption in man. Drug Nutr Interact (1983) 2, 139–44.	6678751
Kennedy MC, Wade DN. The effect of food on the absorption of phenytoin. Aust N Z J Med (1982) 12, 258–61.	6956293
Longe RL, Smith OB. Phenytoin interaction with an oral feeding results in loss of seizure control. J Am Geriatr Soc (1988) 36, 542–4.	3372933
Taylor DM, Massey CA, Willson WG, Dhillon S. Lowered serum phenytoin concentrations during therapy with liquid food concentrates. Ann Pharmacother (1993) 27, 369.	8453178
Nishimura LY, Armstrong EP, Plezia PM, Iacono RP. Influence of enteral feedings on phenytoin sodium absorption from capsules. Drug Intell Clin Pharm (1988) 22, 130–3.	3127188
Guidry JR, Eastwood TF, Curry SC. Phenytoin absorption in volunteers receiving selected enteral feedings. West J Med (1989) 150, 659–61.	2501937
Summers VM, Grant R. Nasogastric feeding and phenytoin interaction. Pharm J (1989) 243, 181.	2492043
Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology (1982) 32, 570–2.	6803191
Ozuna J, Friel P. Effect of enteral tube feeding on serum phenytoin levels. J Neurosurg Nurs (1984) 16, 289–91.	6438282
Worden JP, Wood CA, Workman CH. Phenytoin and nasogastric feedings. Neurology (1984) 34, 132.	6419147
Hatton RC. Dietary interaction with phenytoin. Clin Pharm (1984) 3, 110–11.	6723218
Weinryb J, Cogen R. Interaction of nasogastric phenytoin and enteral feeding solution. J Am Geriatr Soc (1989) 37, 195–6.	2492043
Maynard GA, Jones KM, Guidry JR. Phenytoin absorption from tube feedings. Arch Intern Med (1987) 147, 1821.	3116961
Doak KK, Haas CE, Dunnigan KJ, Reiss RA, Reiser JR, Huntress J, Altavela JL. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy (1998) 18, 637–45.	9620116
Rodman DP, Stevenson TL, Ray TR. Phenytoin malabsorption after jejunostomy tube delivery. Pharmacotherapy (1995) 15, 801–5.	8602393
Miller SW, Strom JG. Stability of phenytoin in three enteral nutrient formulas. Am J Hosp Pharm (1988) 45, 2529–32.	3228106
Hooks MA, Longe RL, Taylor AT, Francisco GE. Recovery of phenytoin from an enteral nutrient formula. Am J Hosp Pharm (1986) 43, 685–8.	3085485
Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM. Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. Epilepsia (1987) 28, 706–12.	3121288
Fleisher D, Sheth N, Kou JH. Phenytoin interaction with enteral feedings administered through nasogastric tubes. J Parenter Enteral Nutr (1990) 14, 513–16.	2122025
Faraji B, Yu P-P. Serum phenytoin levels of patients on gastrostomy tube feeding. J Neurosci Nurs (1998) 30, 55–9.	9604823
Issy AM, Lanchote VL, de Carvalho D, Silva HC. Lack of kinetic interaction between valproic acid and citrus pectin. Ther Drug Monit (1997) 19, 516–20.	9357093
Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther (2002) 71, 11–20.	11823753
Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther (2005) 77, 170–7.	15735611
Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther (1996) 59, 383–8.	8612381
Honig PK, Wortham DC, Lazarev A, Cantilena LR. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol (1996) 36, 345–51.	8728348
Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol (1997) 52, 311–15.	9248771
Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG. Grapefruit juice–terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther (1997) 61, 401–9.	9129557
Wang Z, Hamman MA, Huang S-M, Lesko LJ, Hall SD. Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 71, 414–20.	12087344
Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin Pharmacol Ther (2003) 73, 41–50.	12545142
Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia (1996) 16, 323–7.	8869767
Bobik A, Jennings G, Skews H, Esler M, McLean A. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. Clin Pharmacol Ther (1981) 30, 673–9.	6794970
Gatterer R. Ergotism as complication of thromboembolic prophylaxis with heparin and dihydroergotamine. Lancet (1986) II, 638–639.	2875358
Rem JA, Gratzl O, Follath F, Pult I. Ergotism as complication of thromboembolic prophylaxis with heparin-dihydroergotamine. Lancet (1987) I, 219.	2880045
Schran HF, Bitz DW, DiSerio FJ, Hirsh J. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. Thromb Res. (1983) 31, 51–67.	6612697
Horowitz RS, Dart RC, Gomez HF. Clinical ergotism with lingual ischemia induced by a clarithromycin-ergotamine interaction. Arch Intern Med (1996) 156, 456–8.	8607732
Ausband SC, Goodman PE. An unusual case of clarithromycin associated ergotism. J Emerg Med (2001) 21, 411–13.	11728770
Francis H, Tyndall A, Webb J. Severe vascular spasm due to erythromycin-ergotamine interaction. Clin Rheumatol (1984) 3, 243–6.	6236021
Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C. Dihydroergotamine-erythromycin-induced ergotism. Ann Intern Med (1988) 109, 249.	3389610
Ghali R, De Léan J, Douville Y, Noël H-P, Labbé R. Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy. Ann Vasc Surg (1993) 7, 291–6.	8391300
Bird PA, Sturgess AD. Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin-ergotamine interaction. Aust N Z J Med (2000) 30, 635–6.	11108077
Karam B, Farah E, Ashoush R, Jebara V, Ghayad E. Ergotism precipitated by erythromycin: a rare case of vasospasm. Eur J Vasc Endovasc Surg (2000) 19, 96–8.	10706847
Couet W, Mathieu HP, Fourtillan JB. Effect of ponsinomycin on the pharmacokinetics of dihydroergotamine administered orally. Fundam Clin Pharmacol (1991) 5, 47–52.	2066050
Hayton AC. Precipitation of acute ergotism by triacetyloleandomycin. N Z Med J (1969) 69, 42.	5304704
Matthews NT, Havill JH. Ergotism with therapeutic doses of ergotamine tartrate. N Z Med J (1979) 89, 476–7.	314074
Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother (1985) 16 (Suppl A), 181–94.	3877043
Hopkins S. Clinical toleration and safety of azithromycin. Am J Med (1991) 91 (Suppl 3A), 40S–45S.	1656742
Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis (1991) 10, 807–12.	1662623
Joyce DA, Gubbay SS. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. BMJ (1982) 285, 260–1.	6807440
Galer BS, Lipton RB, Solomon S, Newman LC, Spierings ELH. Myocardial ischemia related to ergot alkaloids: a case report and literature review. Headache (1991) 31, 446–50.	1774159
Vaughan-Lane T. Gangrene induced by methysergide and ergotamine. J Bone Joint Surg Br. (1979) 61–B, 213–14.	438273
Rosenthal E, Sala F, Chichmanian R-M, Batt M, Cassuto J-P. Ergotism related to concurrent administration of ergotamine tartrate and indinavir. JAMA (1999) 281, 987.	10086430
Mortier E, Pouchot J, Vinceneux P, Lalande M. Ergotism related to interaction between nelfinavir and ergotamine. Am J Med (2001) 110, 594.	11347624
Phan TG, Agaliotis D, White G, Britton WJ. Ischaemic peripheral neuritis secondary to ergotism associated with ritonavir therapy. Med J Aust (1999) 171, 502, 504.	10615351
Pardo Rey C, Yebra M, Borrallo M, Vega A, Ramos A, Montero MC. Irreversible coma, ergotamine and ritonavir. Clin Infect Dis (2003) 37, e72–3.	12942422
Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW. Fatal ergotism induced by an HIV protease inhibitor. Headache (2002) 42, 694–5.	12482227
Liaudet L, Buclin T, Jaccard C, Eckert P. Severe ergotism associated with interaction between ritonavir and ergotamine. BMJ (1999) 318, 771.	10082701
Vila A, Mykietiuk A, Bonvehì P, Temporiti E, Urueña A, Herrera F. Clinical ergotism induced by ritonavir. Scand J Infect Dis (2001) 33, 788–9.	11728055
Baldwin ZK, Ceraldi C. Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg (2003) 37, 676–8.	12618710
Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W. Cerebral ergotism under treatment with ergotamine and ritonavir. Neurology (2001) 57, 743–4.	11524501
Gunnarsson P O, Davidsson T, Andersson S-B, Backman C, Johansson S-Å. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol (1990) 38, 189–93.	2338118
Boyle FM. Adverse interaction of herbal medicine with breast cancer treatment. Med J Aust (1997) 167, 286.	9315022
Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med (1997) 336, 1108.	9091822
Ly J, Percy L, Dhanani S. Use of dietary supplements and their interactions with prescription drugs in the elderly. Am J Health-Syst Pharm (2002) 59, 1759–62.	12391711
Makino T, Wakushima H, Okamoto T, Okukubo Y, Deguchi Y, Kano Y. Pharmacokinetic and pharmacological interactions between ticlopidine hydrochloride and Kangen-Karyu – Chinese traditional herbal medicine. Phytother Res (2003) 17, 1021–4.	14595580
Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology (1996) 46, 1775–6.	8649594
Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet (1998) 352, 36.	9800751
Gilbert GJ. Ginkgo biloba. Neurology (1997) 48, 1137.	15344253
Benjamin J, Muir T, Briggs K, Pentland B. A case of cerebral haemorrhage – can Ginkgo biloba be implicated? Postgrad Med J (2001) 77, 112–13.	11161079
Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg (2001) 67, 33–5.	11206893
Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet (1999) 37 (Suppl 2), 13–23.	10702883
Smits P, Aengevaeren WRM, Corstens FHM, Thien T. Caffeine reduces dipyridamole-induced myocardial ischemia. J Nucl Med (1989) 30, 1723–6.	2795213
Smits P, Straatman C, Pijpers E, Thien T. Dose-dependent inhibition of the hemodynamic response to dipyridamole by caffeine. Clin Pharmacol Ther (1991) 50, 529–37.	1934866
Daley PJ, Mahn TH, Zielonka JS, Krubsack AJ, Akhtar R, Bamrah VS. Effect of maintenance oral theophylline on dipyridamole–thallium-201 myocardial imaging using SPECT and dipyridamole-induced hemodynamic changes. Am Heart J (1988) 115, 1185–92.	3259827
Ranhosky A, Kempthorne-Rawson J, and the Intravenous Dipyridamole Thallium Imaging Study Group. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Circulation (1990) 81, 1205–9.	2107985
Mikkelsen EJ. Caffeine and schizophrenia. J Clin Psychiatry (1978) 39, 732–5.	214657
Kulhanek F, Linde OK, Meisenberg G. Precipitation of antipsychotic drugs in interaction with coffee or tea. Lancet (1979) ii, 1130.	501875
Hirsch SR. Precipitation of antipsychotic drugs in interaction with tea or coffee. Lancet (1979) ii, 1130–1.	10243361
Lasswell WL, Wilkins JM, Weber SS. In vitro interaction of selected drugs with coffee, tea, and gallotannic acid. Drug Nutr Interact (1984) 2, 235–41.	6149298
Lasswell WL, Weber SS, Wilkins JM. In vitro interaction of neuroleptics and tricyclic antidepressants with coffee, tea, and gallotannic acid. J Pharm Sci (1984) 73, 1056–8.	6149298
Curry ML, Curry SH, Marroum PJ. Interaction of phenothiazine and related drugs and caffeinated beverages. DICP Ann Pharmacother (1991) 25, 437–8.	1681621
Cheeseman HJ, Neal MJ. Interaction of chlorpromazine with tea and coffee. Br J Clin Pharmacol (1981) 12, 165–9.	7197984
Bowen S, Taylor KM, Gibb IAM. Effect of coffee and tea on blood levels and efficacy of antipsychotic drugs. Lancet (1981) i, 1217–18.	6112560
Wallace SM, Suveges LG, Blackburn JL, Korchinski ED, Midha KK. Oral fluphenazine and tea and coffee drinking. Lancet (1981) ii, 691.	6116064
Gorski JC, Huang S-M, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 75, 89–100.	14749695
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther (2004) 76, 428–40.	15536458
Bareggi SR, Pirola R, Truci G, Leva S, Smirna S. Effect of after-dinner administration on the pharmacokinetics of oral flunitrazepam and loprazolam. J Clin Pharmacol (1988) 28, 371–5.	3392235
Yasui-Furukori N, Takahata T, Kondo T, Mihara K, Kaneko S, Tateishi T. Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam. Br J Clin Pharmacol (2003) 55, 382–8.	12680887
Kim Y, Morikawa M, Ohsawa H, Kou M, Ishida E, Igarashi J, Kajimoto T, Danno T, Nakata M, Yokoyama T, Tokuyama A, Nakamura Y, Kishimoto T. Effects of food on the pharmacokinetics and clinical efficacy of quazepam. Jpn J Neuropsychopharmacol (2003) 23, 205–10.	14653226
Yasui-Furukori N, Kondo T, Takahata T, Mihara K, Ono S, Kaneko S, Tateishi T. Effect of dietary fat content in meals on pharmacokinetics of quazepam. J Clin Pharmacol (2002) 42, 1335–40.	12463728
Markowitz JS, Donovan JL, DeVane CL, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol (2003) 23, 576–81.	14663456
Özdemir M, Aktan Y, Boydağ BS, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet (1998) 23, 55–9.	9625273
Sugimoto K-I, Araki N, Ohmori M, Harada K-I, Cui Y, Tsuruoka S, Kawaguchi A, Fujimura A. Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol (2006) 62, 209–15.	16416305
Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther (1995) 58, 20–8.	7628179
Vanakoski J, Mattila MJ, Seppälä T. Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol (1996) 50, 501–8.	8971132
Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther (1995) 58, 127–31.	7648762
Lilja JJ, Kivistö KT, Backman JT, Neuvonen PJ. Effect of grapefruit juice dose on grapefruit juice–triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol (2000) 56, 411–15.	11009051
Tuncok Y, Akpinar O, Guven H, Akkoclu A. The effects of theophylline on serum alprazolam levels. Int J Clin Pharmacol Ther (1994) 32, 642–5.	7881701
Stirt JA. Aminophylline is a diazepam antagonist. Anesth Analg (1981) 60, 767–8.	7197483
Niemand D, Martinell S, Arvidsson S, Svedmyr N, Ekström-Jodal B. Aminophylline inhibition of diazepam sedation: is adenosine blockade of GABA-receptors the mechanism? Lancet (1984) i, 463–4.	6142202
Arvidsson SB, Ekström-Jodal B, Martinell SAG, Niemand D. Aminophylline antagonises diazepam sedation. Lancet (1982) 2, 1467.	6129542
Kleindienst G, Usinger P. Diazepam sedation is not antagonised completely by aminophylline. Lancet (1984) 1, 113.	6522416
Mattila MJ, Nuotto E. Caffeine and theophylline counteract diazepam effects in man. Med Biol (1983) 61, 337–43.	6374311
Mattila MJ, Palva E, Savolainen K. Caffeine antagonizes diazepam effects in man. Med Biol (1982) 60, 121–3.	7098543
Henauer SA, Hollister LE, Gillespie HK, Moore F. Theophylline antagonizes diazepam-in-duced psychomotor impairment. Eur J Clin Pharmacol (1983) 25, 743–7.	6662173
Meyer BH, Weis OF, Müller FO. Antagonism of diazepam by aminophylline in healthy volunteers. Anesth Analg (1984) 63, 900–2.	6486489
Gürel A, Elevli M, Hamulu A. Aminophylline reversal of flunitrazepam sedation. Anesth Analg (1987) 66, 333–6.	3565796
Wangler MA, Kilpatrick DS. Aminophylline is an antagonist of lorazepam. Anesth Analg (1985) 64, 834–6.	4014747
Kanto J, Aaltonen L, Himberg J-J, Hovi-Viander M. Midazolam as an intravenous induction agent in the elderly: a clinical and pharmacokinetic study. Anesth Analg (1986) 65, 15–20.	2876719
Gallen JS. Aminophylline reversal of midazolam sedation. Anesth Analg (1989) 69, 268.	2764304
Sleigh JW. Failure of aminophylline to antagonize midazolam sedation. Anesth Analg (1986) 65, 540.	2938522
Mattila ME, Mattila MJ, Nuotto E. Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects. Pharmacol Toxicol (1992) 70, 286–9.	1351673
Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet (1995) 29, 142–53.	8521677
Ghoneim MM, Hinrichs JV, Chiang C-K, Loke WH. Pharmacokinetic and pharmacodynamic interactions between caffeine and diazepam. J Clin Psychopharmacol (1986) 6, 75–80.	3517081
Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther (1998) 64, 655–60.	9871430
Dannawi M. Possible serotonin syndrome after combination of buspirone and St John’s wort. J Psychopharmacol (2002) 16, 401.	12503845
Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj (2002) 16, 359–67.	11953006
Raaska K, Raitasuo V, Laitila J, Neuvonen PJ. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol (2004) 94, 13–18.	14725610
Hägg S, Spigset O, Mjörndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol (2000) 49, 59–63.	10606838
Vainer JL, Chouinard G. Interaction between caffeine and clozapine. J Clin Psychopharmacol (1994) 14, 284–5.	7962690
Odom-White A, de Leon J. Clozapine levels and caffeine. J Clin Psychiatry (1996) 57, 175–6.	8601555
Carrillo JA, Jerling M, Bertilsson L. Comments to “Interaction between caffeine and clozapine”. J Clin Psychopharmacol (1995) 15, 376–7.	8830073
Lane H-Y, Chiu C-C, Kazmi Y, Desai H, Lam YWF, Jan MW, Chang W-H. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. Drug Metabol Drug Interact (2001) 18, 263–78.	11791889
Yasui N, Kondo T, Suzuki A, Otani K, Mihara K, Furukori H, Kaneko S, Inoue Y. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. Int Clin Psychopharmacol (1999) 14, 113–8.	10220126
de Maat MMR, Hoetelmans RMW, Mathôt RAA, van Gorp ECM, Meenhorst PL, Mulder JW, Beijnen JH. Drug interaction between St John’s wort and nevirapine. AIDS (2001) 15, 420–1.	11570073
Carver PL, Fleisher D, Zhou SY, Kaul D, Kazanjian P, Li C. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm Res (1999) 16, 718–24.	10350016
Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis (2002) 34, 234–8.	11740713
Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol (2003) 55, 199–202.	12580992
Penzak SR, Acosta EP, Turner M, Edwards DJ, Hon YY, Desai HD, Jann MW. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol (2002) 42, 1165–70.	12362932
Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krähenbühl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol (1998) 45, 355–9.	9578182
Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol (1999) 48, 543–52.	10583025
Melander A, Danielson K, Scherstén B, Wåhlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther (1977) 22, 108–12.	872491
Liedholm H, Melander A. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin Pharmacol Ther (1986) 40, 29–36.	3720177
McLean AJ, Isbister C, Bobik A, Dudley F. Reduction of first-pass hepatic clearance of propranolol by food. Clin Pharmacol Ther (1981) 30, 31–4.	7237895
Daneshmend TK, Roberts CJC. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. Br J Clin Pharmacol (1982) 14, 73–8.	7104169
Dawes CP, Kendall MJ, Welling PG. Bioavailability of conventional and slow-release oxprenolol in fasted and nonfasted individuals. Br J Clin Pharmacol (1979) 7, 299–302.	427007
John VA, Smith SE. Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations. Br J Clin Pharmacol (1985) 19, 191S–195S.	4005122
Kiger JL, Lavene D, Guillaume MF, Guerret M, Longchampt J. The effect of food and clopamide on the absorption of pindolol in man. Int J Clin Pharmacol Biopharm (1976) 13, 228–32.	780287
Melander A, Stenberg P, Liedholm H, Scherstén B, Wåhlin-Boll E. Food-induced reduction in bioavailability of atenolol. Eur J Clin Pharmacol (1979) 16, 327–30.	520399
Lilja JJ, Raaska K, Neuvonen PJ. Effects of grapefruit juice on the pharmacokinetics of acebutolol. Br J Clin Pharmacol (2005) 60, 659–63.	16305592
Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol (2005) 61, 337–40.	15983823
Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther (2003) 73, 192–8.	12621384
Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavailability of the β -adrenergic-blocking agent celiprolol. Clin Pharmacol Ther (2004) 75, 184–90.	15001969
Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther (2005) 77, 291–301.	15903127
Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci (2001) 12, 361–7.	11231102
Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet (1991) 337, 268–9.	1672944
Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JMO. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med (1989) 12, 357–62.	2612087
Edgar B, Bailey D, Bergstrand R, Johnsson G, Regårdh CG. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine – and its potential clinical relevance. Eur J Clin Pharmacol (1992) 42, 313–17.	1577050
Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice–felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther (1993) 53, 637–42.	8513655
Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther (1996) 60, 25–33.	8689808
Lundahl JUE, Regårdh CG, Edgar B, Johnsson G. The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol (1998) 54, 75–81.	9591935
Lundahl J, Regårdh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion – pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol (1997) 52, 139–45.	9174684
Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther (2001) 69, 14–23.	11180034
Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice—felodipine interaction in the elderly. Clin Pharmacol Ther (2000) 68, 28–34.	10945313
Bailey DG, Arnold JMO, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol (1995) 40, 135–40.	8562295
Lundahl J, Regårdh CG, Edgar B, Johnsson G. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol (1995) 49, 61–7.	8751023
Uno T, Ohkubo T, Sugawara K, Higashiyama A, Motomura S, Ishizaki T. Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: evidence for dominant presystemic elimination at the gut site. Eur J Clin Pharmacol (2000) 56, 643–9.	11214770
Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A. Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation. Pharmazie (1994) 49, 522–4.	8073064
Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol (1995) 40, 51–8.	8527268
Fuhr U, Maier-Brüggemann A, Blume H, Mück W, Unger S, Kuhlmann J, Huschka C, Zaigler M, Rietbrock S, Staib AH. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther (1998) 36, 126–32.	9562227
Soons PA, Vogels BAPM, Roosemalen MCM, Schoemaker HC, Uchida E, Edgar B, Lundahl J, Cohen AF, Breimer DD. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther (1991) 50, 394–403.	1914375
Bailey DG, Arnold JMO, Strong HA, Munoz C, Spence JD. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther (1993) 54, 589–94.	8275614
Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furuie H, Matsukuma K, Kimura M, Kawano K, Orii Y, Tanaka T, Sawada Y. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther (2000) 67, 201–14.	10741622
Josefsson M, Zackrisson A-L, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol (1996) 51, 189–93.	8911887
Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol (2000) 50, 455–63.	11069440
Josefsson M, Ahlner J. Amlodipine and grapefruit juice. Br J Clin Pharmacol (2002) 53, 405.	11966676
Ohtani M, Kawabata S, Kariya S, Uchino K, Itou K, Kotaki H, Kasuyama K, Morikawa A, Seo I, Nishida N. Effect of grapefruit pulp on the pharmacokinetics of the dihydropyridine calcium antagonists nifedipine and nisoldipine. Yakugaku Zasshi (2002) 122, 323–9.	12040751
Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther (2000) 68, 468–77.	11103749
Sigusch H, Henschel L, Kraul H, Merkel U, Hoffman A. Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. Pharmazie (1994) 49, 675–9.	7972311
Christensen H, Åsberg A, Holmboe A-B, Berg KJ. Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. Eur J Clin Pharmacol (2002) 58, 515–20.	12451428
Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, Blatt A, Golik A. The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. Eur J Clin Pharmacol (1998) 54, 337–40.	9696960
Ho P-C, Ghose K, Saville D, Wanwimolruk S. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol (2000) 56, 693–8.	11214778
Fuhr U, Müller-Peltzer H, Kern R, Lopez-Rojas P, Jünemann M, Harder S, Staib AH. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol (2002) 58, 45–53.	11956673
Chayen R, Rosenthal T. Interaction of citrus juices with felodipine and nifedipine. Lancet (1991) 337, 854.	1672944
Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther (2003) 73, 529–37.	12811362
Goosen TC, Cillié D, Bailey DG, Yu C, He K, Hollenberg PF, Woster PM, Cohen L, Williams JA, Rheeders M, Dijkstra HP. Bergamottin contribution to the grapefruit juice—felodipine interaction and disposition in humans. Clin Pharmacol Ther (2004) 76, 607–17.	15592332
Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of first-pass metabolism. Clin Pharmacol Ther (2004) 75, 298–309.	15060508
Melander A, Danielson K, Hanson A, Rudell B, Schersten B, Thulin T, Wåhlin E. Enhancement of hydralazine bioavailability by food. Clin Pharmacol Ther (1977) 22, 104–7.	872490
Liedholm H, Wåhlin-Boll E, Hanson A, Melander A. Influence of food on the bioavailability of ‘real’ and ‘apparent’ hydralazine from conventional and slow-release preparations. Drug Nutr Interact (1982) 1, 293–302.	6926836
Walden RJ, Hernadez R, Witts D, Graham BR, Prichard BN. Effect of food on the absorption of hydralazine in man. Eur J Clin Pharmacol (1981) 20, 53–8.	7308273
Shepherd AM, Irvine NA, Ludden TM. Effect of food on blood hydralazine levels and response in hypertension. Clin Pharmacol Ther (1984) 36, 14–18.	6734044
Jackson SHD, Shepherd AMM, Ludden TM, Jamieson MJ, Woodworth J, Rogers D, Ludden LK, Muir KT. Effect of food on oral bioavailability of apresoline and controlled release hydralazine in hypertensive patients. J Cardiovasc Pharmacol (1990) 16, 624–8.	1706804
Semple HA, Koo W, Tam YK, Ngo LY, Coutts RT. Interactions between hydralazine and oral nutrients in humans. Ther Drug Monit (1991) 13, 304–8.	1780961
Wang D-J, Chu K-M, Chen J-D. Drug interaction between digoxin and bisacodyl. J Formos Med Assoc (1990) 89, 913, 915–9.	1981783
Woods MN, Ingelfinger JA. Lack of effect of bran on digoxin absorption. Clin Pharmacol Ther (1979) 26, 21–3.	445958
Nordström M, Melander A, Robertsson E, Steen B. Influence of wheat bran and of a bulk-forming ispaghula cathartic on the bioavailability of digoxin in geriatric in-patients. Drug Nutr Interact (1987) 5, 67–9.	3038494
Johnson BF, Rodin SM, Hoch K, Shekar V. The effect of dietary fiber on the bioavailability of digoxin in capsules. J Clin Pharmacol (1987) 27, 487–90.	2821081
Brown DD, Juhl RP, Warner SL. Decreased bioavailability of digoxin due to hypocholesterolemic interventions. Circulation (1978) 58, 164–72.	647881
Huupponen R, Seppälä P, Iisalo E. Effect of guar gum, a fibre preparation, on digoxin and penicillin absorption in man. Eur J Clin Pharmacol (1984) 26, 279–81.	6327318
Lembcke B, Häsler K, Kramer P, Caspary WF, Creuzfeldt W. Plasma digoxin concentrations during administration of dietary fibre (guar gum) in man. Z Gastroenterol (1982) 20, 164–7.	6282000
Ragueneau I, Poirier J-M, Radembino N, Sao AB, Funck-Brentano C, Jaillon P. Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. Br J Clin Pharmacol (1999) 48, 453–6.	10510161
Floyd RA. Digoxin interaction with bran and high fiber foods. Am J Hosp Pharm (1978) 35, 660.	665675
Hamamura J, Burros BC, Clemens RA, Smith CH. Dietary fiber and digoxin. Fedn Proc (1985) 44, 759.	2985676
Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther (2001) 70, 311–6.	11673746
Parker RB, Yates CR, Soberman JE, Laizure SC. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy (2003) 23, 979–87.	12921244
Xu J, Go ML, Lim L-Y. Modulation of digoxin transport across Caco-2 cell monolayers by citrus fruit juices: lime, lemon, grapefruit and pummelo. Pharm Res (2003) 20, 169–76.	12636154
Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song P-f, Hubbard MA, Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2006) 34, 69–74.	16221754
Longerich L, Johnson E, Gault MH. Digoxin-like factors in herbal teas. Clin Invest Med (1993) 16, 210–8.	8395986
Sweetman SC, ed.Martindale. The complete drug reference. 35 th ed.London: Pharmaceutical Press; (2007). p.2188.	18226589
Thürmann PA, Neff A, Fleisch J. Interference of uzara glycosides in assays of digitalis glycosides. Int J Clin Pharmacol Ther (2004) 42, 281–4.	15176651
Dasgupta A, Davis B, Wells A. Effect of plantain on therapeutic drug monitoring of digoxin and thirteen other common drugs. Ann Clin Biochem (2006) 43, 223–5.	16704760
Slifman NR, Obermeyer WR, Aloi BK, Musser SM, Correll WA, Cichowicz SM, Betz JM, Love LA. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med (1998) 339, 806–11.	9738088
Mauro VF, Mauro LS, Kleshinski JF, Khuder SA, Wang Y, Erhardt PW. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther (2003) 10, 247–51.	12845387
Dasgupta A, Wu S, Actor J, Olsen M, Wells A, Datta P. Effect of Asian and Siberian ginseng on serum digoxin measurement by five digoxin immunoassays. Significant variation in digoxin-like immunoreactivity among commercial ginsengs. Am J Clin Pathol (2003) 119, 298–303.	12580002
Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2007) 35, 240–5.	17079360
Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2007) 35, 240–5.	17079360
Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song P-f, Hubbard MA, Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2006) 34, 69–74.	16221754
Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther (1999) 66, 338–45.	10546917
Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl E-M, Sievers H, Frank B, Riethling A-K, Drewelow B. Effect of St John’s wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther (2004) 75, 546–57.	15179409
Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med (2005) 71, 331–337.	15856409
Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St John’s wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther (2000) 68, 598–604.	11180019
Gibbs CJ, Lee HA. Milk-alkali syndrome due to Caved-S. J R Soc Med (1992) 85, 498–9.	1404208
Gordon MV, Hamblin PS, McMahon LP. Life-threatening milk-alkali syndrome resulting from antacid ingestion during pregnancy. Med J Aust (2005) 182, 350–351.	16116693
McGuinness B, Logan JI. Milk alkali syndrome. Ulster Med J (2002) 71, 132–5.	17546822
Ennen CS, Magann EF. Milk-alkali syndrome presenting as acute renal insufficiency during pregnancy. Obstet Gynecol (2006) 108, 785–6.	17018502
George S, Clark JDA. Milk alkali syndrome – an unusual syndrome causing an unusual complication. Postgrad Med J (2000) 76, 422–4.	10878206
Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T. Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes. J Clin Pharmacol (2005) 45, 690–4.	15901751
Tassaneeyakul W, Tassaneeyakul W, Vannaprasaht S, Yamazoe Y. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br J Clin Pharmacol (2000) 49, 139–44.	11501187
Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS. Pharmacogenetics and herb–drug interactions: experience with Gingko biloba and omeprazole. Pharmacogenetics (2004) 14, 841–50.	15608563
Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D, Zhong XY, Zhou HH. St John’s wort induces both cytochrome P450 3A4–catalyzed sulfoxidation and 2C19–dependent hydroxylation of omeprazole. Clin Pharmacol Ther (2004) 75, 191–7.	15001970
Schubert W, Cullberg G, Edgar B, Hedner T. Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women. Maturitas (1994) 20, 155–63.	7715468
Weber A, Jäger R, Börner A, Klinger G, Vollanth R, Matthey K, Balogh A. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception (1996) 53, 41–7.	8631189
Keogh A, Day R, Critchley L, Duggin G, Baron D. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc (1988) 20, 27–30.	3278460
Santos P, Lourenço R, Camilo ME, Oliveira AG, Figueira I, Pereira ME, Ferreira B, Carmo JA, Lacerda JMF. Parenteral nutrition and cyclosporine: do lipids make a difference? A prospective randomized crossover trial. Clin Nutr (2001) 20, 31–6.	11161541
Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol (1993) 36, 457–9.	12959294
Yee GC, Stanley DL, Pessa LJ, Costa TD, Beltz SE, Ruiz J, Lowenthal DT. Effect of grapefruit juice on blood cyclosporine concentration. Lancet (1995) 345, 955–6.	7677856
Proppe DG, Hoch OD, McLean AJ, Visser KE. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol (1995) 39, 337–8.	7619679
Min DI, Ku Y-M, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation (1996) 62, 123–5.	8693526
Herlitz H, Edgar B, Hedner T, Lidman K, Karlberg I. Grapefruit juice: a possible source of variability in blood concentration of cyclosporin A. Nephrol Dial Transplant (1993) 8, 375.	8390020
Brunner L, Munar MY, Vallian J, Wolfson M, Stennett DJ, Meyer MM, Bennett WM. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients. Pharmacotherapy (1998) 18, 23–9.	9469677
Emilia G, Longo G, Bertesi M, Gandini G, Ferrara L, Valenti C. Clinical interaction between grapefruit juice and cyclosporine: is there any interest for the hematologists? Blood (1998) 91, 362–3.	9414309
Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, Watkins P. 6’,7’-dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther (1999) 65, 237–44.	10096255
Ku Y-M, Min DI, Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J Clin Pharmacol (1998) 38, 959–65.	9807978
Ioannides-Demos LL, Christophidis N, Ryan P, Angelis P, Liolios L, McLean AJ. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol (1997) 24, 49–54.	9002010
Hollander AAMJ, van Rooij J, Lentjes EGWM, Arbouw F, van Bree JB, Schoemaker RC, van Es LA, van der Woude FJ, Cohen AF. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther (1995) 57, 318–24.	7697949
Mehrsai AR, Pourmand G, Mansour D, Zand S, Rezaali A. Effect of grapefruit juice on serum concentration of cyclosporine in Iranian renal transplant patients. Transplant Proc (2003) 35, 2739–41.	14612100
Lee M, Min DI, Ku Y-M, Flanigan M. Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter? J Clin Pharmacol (2001) 41, 317–23.	11269572
Brunner LJ, Pai K-S, Munar MY, Lande MB, Olyaei AJ, Mowry JA. Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant (2000) 4, 313–21.	11079273
Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther (1995) 57, 485–91.	7768070
Johnston A, Holt DW. Effect of grapefruit juice on blood cyclosporin concentration. Lancet (1995) 346, 122–3.	7677856
Hollander AAMJ, van der Woude FJ, Cohen AF. Effect of grapefruit juice on blood cyclosporin concentration. Lancet (1995) 346, 123.	7677856
Yee GC, Lowenthal DT. Effect of grapefruit juice on blood cyclosporin concentration. Lancet (1995) 346, 123–4.	7677856
Light TD, Light JA. Acute renal transplant rejection possibly related to herbal medications. Am J Transplant (2003) 3, 1608–9.	14629295
Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol (2005) 61, 567–72.	16133554
Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol (2006) 28, 25–9.	16541194
Choi JS, Choi BC, Choi KE. Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am J Health-Syst Pharm (2004) 61, 2406–9.	15581264
Breidenbach Th, Hoffmann MW, Becker Th, Schlitt H, Klempnauer J. Drug interaction of St John’s wort with ciclosporin. Lancet (2000) 355, 1912.	11180020
Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J. Profound drop of cyclosporin A whole blood trough levels caused by St John’s wort (Hypericum perforatum). Transplantation (2000) 69, 2229–30.	10852634
Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation (2001) 71, 239–41.	11871046
Mai I, Kreuger H, Budde K, Johne A, Brockmoeller J, Neumayer H-H, Roots I. Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther (2000) 38, 500–2.	11073292
Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St John’s wort and cyclosporine. Ann Pharmacother (2000) 34, 1013–16.	11180020
Moschella PA-C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St John’s wort) after organ transplantation. Am J Kidney Dis (2001) 38, 1105–7.	11871046
Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. St John’s wort: a hidden risk for transplant patients. Prog Transplant (2001) 11, 116–20.	11871046
Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. Acute heart transplant rejection due to Saint John’s wort. Lancet (2000) 355, 548–9.	10683008
Ahmed SM, Banner NR, Dubrey SW. Low cyclosporin-A level due to Saint-John’s-wort in heart-transplant patients. J Heart Lung Transplant (2001) 20, 795.	11474706
Alscher DM, Klotz U. Drug interaction of herbal tea containing St. John’s wort with cyclosporine. Transpl Int (2003) 16, 543–4.	12677367
Bauer S, Störmer E, Johne A, Krüger H, Budde K, Neumayer H-H, Roots I, Mai I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John’s wort in renal transplant patients. Br J Clin Pharmacol (2003) 55, 203–11.	12580993
Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St John’s wort–cyclosporine drug interaction. Clin Pharmacol Ther (2004) 76, 330–40.	15470332
Chen M-F, Shimada F, Kato H, Yano S, Kanaoka M. Effect of oral administration of glycyrrhizin on the pharmacokinetics of prednisolone. Endocrinol Jpn (1991) 38, 167–74.	1752235
Chen M-F, Shimada F, Kato H, Yano S, Kanaoka M. Effect of glycyrrhizin on the pharmacokinetics of prednisolone following low dosage of prednisolone hemisuccinate. Endocrinol Jpn (1990) 37, 331–41.	2253583
Varis T, Kivistö KT, Neuvonen PJ. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. Eur J Clin Pharmacol (2000) 56, 489–93.	11049012
Hollander AA, van Rooij J, Lentjes EGWM, Arbouw F, van Bree JB, Schoemaker RC, van Es LA, van der Woude FJ, Cohen AF. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther (1995) 57, 318–24.	7697949
Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther (1999) 66, 118–27.	10460065
Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M, Yamazoe Y, Takamura T, Kaneko S, Fujimura A. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol (2005) 60, 494–7.	16236039
Fukazawa I, Uchida N, Uchida E, Yasuhara H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol (2004) 57, 448–55.	15025743
Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther (1998) 63, 397–402.	9585793
Rogers JD, Zhao J, Liu L, Amin RD, Gagliano KD, Porras AG, Blum RA, Wilson MF, Stepanavage M, Vega JM. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther (1999) 66, 358–66.	10546919
Bailey DG, Dresser GK. Grapefruit juice-lovastatin interaction. Clin Pharmacol Ther (2000) 67, 690.	10872652
Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y, Kobayashi S. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci (2006) 78, 2852–9.	16412477
Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis with pomegranate juice consumption. Am J Cardiol (2006) 98, 705–6.	16923466
Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther (1998) 64, 477–83.	9834039
Lilja JJ, Kivistö KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther (2000) 68, 384–90.	11061578
Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol (2004) 58, 56–60.	15206993
Dreier JP, Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology (2004) 62, 670.	14981197
Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakomoto K, Masada M, Miyamori I, Fujimura A. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther (2001) 70, 518–24.	11753267
Richter WO, Jacob BG, Schwandt P. Interaction between fibre and lovastatin. Lancet (1991) 338, 706.	1679514
Mester R, Toren P, Mizrachi I, Wolmer L, Karni N, Weizman A. Caffeine withdrawal increases lithium blood levels. Biol Psychiatry (1995) 37, 348–50.	7748990
Jefferson JW. Lithium tremor and caffeine intake: two cases of drinking less and shaking more. J Clin Psychiatry (1988) 49, 72–3.	3338980
Thomsen K, Schou M. Renal lithium excretion in man. Am J Physiol (1968) 215, 823–7.	5676383
Pyevich D, Bogenschutz MP. Herbal diuretics and lithium toxicity. Am J Psychiatry (2001) 158, 1329.	11481175
Kline NS. Psychopharmaceuticals: effects and side-effects. Bull WHO (1959) 21, 397–410.	13811223
Pakes GE. Phenelzine-cola headache. Am J Hosp Pharm (1979) 36, 736.	463881
Shader RI, Greenblatt DJ. Phenelzine and the dream machine—ramblings and reflections. J Clin Psychopharmacol (1985) 5, 65.	3988971
Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med (1995) 12, 49–51.	7640830
Shader RI, Greenblatt DJ. MAOIs and drug interactions—a proposal for a clearinghouse. J Clin Psychopharmacol (1985) 5, A17.	3998202
Berkowitz BA, Spector S, Pool W. The interaction of caffeine, theophylline and theobromine with monoamine oxidase inhibitors. Eur J Pharmacol (1971) 16, 315–21.	5132558
Hodge JV, Nye ER, Emerson GW. Monoamine-oxidase inhibitors, broad beans, and hypertension. Lancet (1964) i, 1108.	14132623
Blomley DJ. Monoamine-oxidase inhibitors. Lancet (1964) ii, 1181–2.	14254960
McQueen EG. Interactions with monoamine oxidase inhibitors. BMJ (1975) 4, 101.	1195132
Balon R, Pohl R, Yeragani VK, Berchou R, Gershon S. Monosodium glutamate and tranylcypromine administration in healthy subjects. J Clin Psychiatry (1990) 51, 303–6.	2091623
McCabe B, Tsuang MT. Dietary consideration in MAO inhibitor regimens. J Clin Psychiatry (1982) 43, 178–81.	7076627
Lee S, Wing YK. MAOI and monosodium glutamate interaction. J Clin Psychiatry (1991) 52, 3.	1988422
Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry (1967) 113, 349–65.	6034391
Sadusk JF. The physician and the Food and Drug Administration. JAMA (1964) 190, 907–9.	14214493
Hedberg DL, Gordon MW, Glueck BC. Six cases of hypertensive crisis in patients on tranylcypromine after eating chicken livers. Am J Psychiatry (1966) 122, 933–7.	5948152
Isaac P, Mitchell B, Grahame-Smith DG. Monoamine-oxidase inhibitors and caviar. Lancet (1977) ii, 816.	71616
Nuessle WF, Norman FC, Miller HE. Pickled herring and tranylcypromine reaction. JAMA (1965) 192, 726–7.	14280527
Kelly D, Guirguis W, Frommer E, Mitchell-Heggs N, Sargant W. Treatment of phobic states with antidepressants. A retrospective study of 246 patients. Br J Psychiatry (1970) 116, 387–98.	4909796
Abrams JH, Schulman P, White WB. Successful treatment of a monoamine oxidase inhibitor-tyramine hypertensive emergency with intravenous labetalol. N Engl J Med (1985) 313, 52.	4000229
Mesmer RE. Don’t mix miso with MAOIs. JAMA (1987) 258, 3515.	3682151
Zetin M, Plon L, DeAntonio M. MAOI reaction with powdered protein dietary supplement. J Clin Psychiatry (1987) 48, 499.	3693341
McQueen EG. Interactions with monoamine oxidase inhibitors. BMJ (1975) 4, 101.	1195132
Karet FE, Dickerson JEC, Brown J, Brown MJ. Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure. Lancet (1994) 344, 1263–5.	7967987
Berlin I, Zimmer R, Cournot A, Payan C, Pedarriosse AM, Puech AJ. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther (1989) 46, 344–51.	2673623
Bieck PR, Antonin KH. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm (1989) (Suppl 28), 21–31.	2794993
Warrington SJ, Turner P, Mant TGK, Morrison P, Haywood G, Glover V, Goodwin BL, Sandler M, St John-Smith P, McClelland GR. Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor. J Psychopharmacol (1991) 5, 82–91.	22282124
Korn A, Da Prada M, Raffesberg W, Gasic S, Eichler HG. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol (1988) 11, 17–23.	2450251
Burgess CD, Mellsop GW. Interaction between moclobemide and oral tyramine in depressed patients. Fundam Clin Pharmacol (1989) 3, 47–52.	2714732
Audebert C, Blin O, Monjanel-Mouterde S, Auquier P, Pedarriosse AM, Dingemanse J, Durand A, Cano JP. Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers. Eur J Clin Pharmacol (1992) 43, 507–12.	1483487
Provost J-C, Funck-Brentano C, Rovei V, D’Estanque J, Ego D, Jaillon P. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin Pharmacol Ther (1992) 52, 384–93.	1424410
Cooper AJ, Magnus RV, Rose MJ. A hypertensive syndrome with tranylcypromine medication. Lancet (1964) i, 527–9.	14100187
Anon. Hypertensive reactions to monoamine oxidase inhibitors. BMJ (1964) i, 578–9.	14088308
Da Prada M, Zürcher G, Wüthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm (1988) (Suppl 26), 31–56.	3283290
Price K, Smith SE. Cheese reaction and tyramine. Lancet (1971) i, 130–1.	4099618
Hutchison JC. Toxic effects of monoamine-oxidase inhibitors. Lancet (1964) ii, 151.	14172385
Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibitors: a re-examination. Can J Psychiatry (1984) 29, 707–11.	6394124
McCabe BJ. Dietary tyramine and other pressor amines in MAOI regimens: a review. J Am Diet Assoc (1986) 86, 1059–64.	3525654
Brown C, Taniguchi G, Yip K. The monoamine oxidase inhibitor-tyramine interaction. J Clin Pharmacol (1989) 29, 529–32.	2666453
Gardner DM, Shulman KI, Walker SE, Tailor SAN. The making of a user friendly MAOI diet. J Clin Psychiatry (1996) 57, 99–104.	8617704
Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry (1999) 60, 191–3.	10192596
Marcason W. What is the bottom line for dietary guidelines when taking monoamine oxidase inhibitors? J Am Diet Assoc (2005) 105, 163.	15635366
Fier M. Safer use of MAOIs. Am J Psychiatry (1991) 148, 391–2.	1781863
Lippman SB, Nash K. Monoamine oxidase inhibitor update. Potential adverse food and drug interactions. Drug Safety (1990) 5, 195–204.	2396245
Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. Pharmacotherapy (1996) 16, 1046–52.	8947977
Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol (1985) 28, 425–8.	4029248
Patwardhan RV, Desmond PV, Johnson RF, Schenker S. Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med (1980) 95, 603–8.	7359014
Rietveld EC, Broekman MMM, Houben JJG, Eskes TKAB, van Rossum JM. Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids. Eur J Clin Pharmacol (1984) 26, 371–3.	6734698
Balogh A, Klinger G, Henschel L, Börner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol (1995) 48, 161–6.	7589032
Pollock BG, Wylie M, Stack JA, Sorisio DA, Thompson DS, Kirshner MA, Folan MM, Condifer KA. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol (1999) 39, 936–40.	10471985
Brazier JL, Descotes J, Lery N, Ollagnier M, Evreux J-C. Inhibition by idrocilamide of the disposition of caffeine. Eur J Clin Pharmacol (1980) 17, 37–43.	7371698
Russman S, Lauterburg BH, Barguil Y, Choblet E, Cabalion P, Rentsch K, Wenk M. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens? Clin Pharmacol Ther (2005) 77, 451–4.	15900292
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther (2005) 77, 415–26.	15900287
Gelal A, Guven H, Balkan D, Artok L, Benowitz NL. Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers. Eur J Clin Pharmacol (2003) 59, 417–22.	12915954
Bendriss EK, Bechtel Y, Bendriss A, Humbert P, Paintaud G, Megnette J, Agache P, Bechtel PR. Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis. Br J Clin Pharmacol (1996) 41, 421–4.	8735685
Staib AH, Stille W, Dietlein G, Shah PM, Harder S, Mieke S, Beer C. Interaction between quinolones and caffeine. Drugs (1987) 34 (Suppl 1), 170–4.	3481318
Carbó M, Segura J, De la Torre R, Badenas JM, Camí J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther (1989) 45, 234–40.	2686430
Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. 4-Quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol (1988) 35, 651–6.	3053579
Stille W, Harder S, Mieke S, Beer C, Shah PM, Frech K, Staib AH. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J Antimicrob Chemother (1987) 20, 729–34.	3480885
Healy DP, Schoenle JR, Stotka J, Polk RE. Lack of interaction between lomefloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother (1991) 35, 660–4.	2069371
Healy DP, Polk RE, Kanawati L, Rock DT, Mooney ML. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother (1989) 33, 474–8.	2729942
Nicolau DP, Nightingale CH, Tessier PR, Fu Q, Xuan D-w, Esguerra EM, Quintiliani R. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. Drugs (1995) 49 (Suppl 2), 357–9.	8549360
Cesana M, Broccali G, Imbimbo BP, Crema A. Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration. Int J Clin Pharmacol Ther Toxicol (1991) 29, 133–8.	2071262
Kinzig-Schippers M, Fuhr U, Zaigler M, Dammeyer J, Rüsing G, Labedzki A, Bulitta J, Sörgel F. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther (1999) 65, 262–74.	10096258
Kim M-Y, Nightingale CH, Nicolau DP. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine. Clin Pharmacokinet (2003), 42, 985–96.	12908854
Barnett G, Segura J, de la Torre R, Carbó M. Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition. Eur J Clin Pharmacol (1990) 39, 63–9.	2177401
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther (2004) 76, 428–40.	15536458
Saruwatari J, Nakagawa K, Shindo J, Nachi S, Echizen H, Ishizaki T. The in-vivo effects of sho-saiko-to, a traditional Chinese herbal medicine, on two cytochrome P450 enzymes (1A2 and 3A) and xanthine oxidase in man. J Pharm Pharmacol (2003) 55, 1553–9.	14713367
Wenk M, Todesco L, Krähenbühl S. Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol (2004) 57, 494–9.	15025748
Bapiro TE, Sayi J, Hasler JA, Jande M, Rimoy G, Masselle A, Masimirembwa CM. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol (2005) 61, 755–61.	16261361
Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. J Clin Pharmacol (1999) 39, 252–9.	10073324
Karim A, Burns T, Wearley L, Streicher J, Palmer M. Food-induced changes in theophylline absorption from controlled-release formulations. Part I.Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle. Clin Pharmacol Ther (1985) 38, 77–83.	4006379
Lohmann A, Dingler E, Sommer W. Influence of food on the bioavailability of theophylline from a sustained-release theophylline preparation. Arzneimittelforschung (1991) 41, 732–4.	1772462
Johansson Ö, Lindberg T, Melander A, Wåhlin-Boll E. Different effects of different nutrients on theophylline absorption in man. Drug Nutr Interact (1985) 3, 205–11.	4064930
Sips AP, Edelbroek PM, Kulstad S, de Wolff FA, Dijkman JH. Food does not effect bioavailability of theophylline from Theolin Retard. Eur J Clin Pharmacol (1984) 26, 405–7.	25032445
Steffensen G, Pedersen S. Food induced changes in theophylline absorption from a once-a-day theophylline product. Br J Clin Pharmacol (1986) 22, 571–7.	3790404
Ürmös I, Grézal G, Balogh Nemes K, Szállási T, Drabant S, Csörgo M, Klebovich I. Food interaction study of a new theophylline (Egifilin) 200 and 400 mg retard tablet in healthy volunteers. Int J Clin Pharmacol Ther (1997) 35, 65–70.	9147710
González MA, Straughn AB. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. Clin Ther (1994) 16, 804–14.	7859239
Thebault JJ, Aiache JM, Mazoyer F, Cardot JM. The influence of food on the bioavailability of a slow release theophylline preparation. Clin Pharmacokinet (1987) 13, 267–72.	3665325
Lefebvre RA, Belpaire FM, Bogaert MG. Influence of food on steady state serum concentrations of theophylline from two controlled-release preparations. Int J Clin Pharmacol Ther Toxicol (1988) 26, 375–9.	3220610
Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther (1976) 20, 643–53.	991535
Feldman CH, Hutchinson VE, Pippenger CE, Blumenfeld TA, Feldman BR, Davis WJ. Effect of dietary protein and carbohydrate on theophylline metabolism in children. Pediatrics (1980) 66, 956–62.	7454487
Thompson PJ, Skypala I, Dawson S, McAllister WAC, Turner Warwick M. The effect of diet upon serum concentrations of theophylline. Br J Clin Pharmacol (1983) 16, 267–70.	6626418
Anderson KE, McCleery RB, Vesell ES, Vickers FF, Kappas A. Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology (1991) 13, 941–6.	1766062
Gal P, Layson R. Interference with oral theophylline absorption by continuous nasogastric feedings. Ther Drug Monit (1986) 8, 421–3.	3824426
Bhargava VO, Schaaf LJ, Berlinger WG, Jungnickel PW. Effect of an enteral nutrient formula on sustained-release theophylline absorption. Ther Drug Monit (1989) 11, 515–19.	2510372
Plezia PM, Thornley SM, Kramer TH, Armstrong EP. The influence of enteral feedings on sustained-release theophylline absorption. Pharmacotherapy (1990) 10, 356–61.	2122422
Cuddy PG, Bealer JF, Lyman EL, Pemberton LB. Theophylline disposition following parenteral feeding of malnourished patients. Ann Pharmacother (1993) 27, 846–51.	8364261
Pantuck EJ, Pantuck CB, Garland WA, Min BH, Wattenberg LW, Anderson KE, Kappas A, Conney AH. Stimulatory effect of Brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther (1979) 25, 88–95.	758247
Fuhr U, Maier A, Keller A, Steinijans VW, Sauter R, Staib AH. Lacking effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther (1995) 33, 311–14.	7582380
Stewart DE. Venlafaxine and sour date nut. Am J Psychiatry (2004) 161, 1129–30.	15169710
DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS (2001) 15, 1281–5.	11426073
Hori H, Yoshimura R, Ueda N, Eto S, Shinkai K, Sakata S, Ohmori O, Terao T, Nakamura J. Grapefruit juice-fluvoxamine interaction. Is it risky or not? J Clin Psychopharmacol (2003) 23, 422–4.	20301621
Wiens A. How does grapefruit juice affect psychotropic medications? J Psychiatry Neurosci (2000) 25, 198.	10740993
Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs (1998) 30, 367–9.	9924842
Yamada K, Yagi G, Kanba S. Effectiveness of Gorei-san (TJ-17) for treatment of SSRI-induced nausea and dyspepsia: preliminary observations. Clin Neuropharmacol (2003) 26, 112–14.	12782911
Gordon JB. SSRIs and St. John’s wort: possible toxicity? Am Fam Physician (1998) 57, 950–3.	9518947
Lantz MS, Buchalter E, Giambanco V. St. John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol (1999) 12, 7–10.	10636361
Stewart DE. High-fiber diet and serum tricyclic antidepressant levels. J Clin Psychopharmacol (1992) 12, 438–40.	1335461
Liedholm H, Lidén A. Food intake and the presystemic metabolism of single doses of amitriptyline and nortriptyline. Fundam Clin Pharmacol (1998) 12, 636–42.	9818297
Domingo JL, Gomez M, Llobet JM, Richart C. Effect of ascorbic acid on gastrointestinal aluminium absorption. Lancet (1991) 338, 1467.	1683458
Domingo JL, Gomez M, Llobet JM, Corbella J. Influence of some dietary constituents on aluminum absorption and retention in rats. Kidney Int (1991) 39, 598–601.	2051716
Bakir AA, Hryhorczuk DO, Berman E, Dunea G. Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. Trans Am Soc Artif Intern Organs (1986) 32, 171–6.	3778707
Bakir AA, Hryhorczuk DO, Ahmed S, Hessl SM, Levy PS, Spengler R, Dunea G. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol (1989) 31, 40–4.	2914409
Kirschbaum HB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci (1989) 297, 9–11.	2913801
Rudy D, Sica DA, Comstock T, Davis J, Savory J, Schoolwerth AC. Aluminum-citrate interaction in end-stage renal disease. Int J Artif Organs (1991) 14, 625–9.	1748529
Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminium hydroxide. Am J Kidney Dis (1991) 17, 708–11.	2042654
Walker JA, Sherman RA, Cody RP. The effect of oral bases on enteral aluminum absorption. Arch Intern Med (1990) 150, 2037–9.	2171446
Slanina P, Frech W, Ekström L-G, Lööf L, Slorach S, Cedergren A. Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem (1986) 32, 539–41.	3948402
Weberg R, Berstad A. Gastrointestinal absorption of aluminium from single doses of aluminium containing antacids in man. Eur J Clin Invest (1986) 16, 428–32.	3100311
Fairweather-Tait S, Hickson K, McGaw B, Reid M. Orange juice enhances aluminium absorption from antacid preparation. Eur J Clin Nutr (1994) 48, 71–3.	8200332
Dorhout Mees EJ, Basçi A. Citric acid in calcium effervescent tablets may favour aluminium intoxication. Nephron (1991) 59, 322.	1956499
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther (2004) 76, 428–40.	15536458
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther (2005) 77, 415–26.	15900287
Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res (1989) 27, 313–23.	2565585
Markowitz JS, DeVane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther (2003) 74, 170–7.	12891227
Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS. Siberian ginseng (Eleutheroccus [sic] senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos (2003) 31, 519–22.	12695337
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther (2005) 77, 415–26.	15900287
Muñoz LM, Lönnerdal B, Keen CL, Dewey KG. Coffee consumption as a factor in iron deficiency anemia among pregnant women and their infants in Costa Rica. Am J Clin Nutr (1988) 48, 645–51.	3414579
Merhav H, Amitai Y, Palti H, Godfrey S. Tea drinking and microcytic anemia in infants. Am J Clin Nutr (1985) 41, 1210–13.	4003328
Mahlknecht U, Weidmann E, Seipelt G. Black tea delays recovery from iron-deficiency anaemia. Haematologica (2001) 86, 559.	11410431
Russman S, Lauterburg BH, Barguil Y, Choblet E, Cabalion P, Rentsch K, Wenk M. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens? Clin Pharmacol Ther (2005) 77, 451–4.	15900292
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther (2005) 77, 415–26.	15900287
Härtter S, Nordmark A, Rose D-M, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol (2003) 56, 679–682.	14616429
Härtter S, Korhonen T, Lundgren S, Rane A, Tolonen A, Turpeinen M, Laine K. Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin. Basic Clin Pharmacol Toxicol (2006) 99, 300–4.	17089110
Ursing C, Wikner J, Brismar K, Röjdmark S. Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome P450 (CYP)1A2. J Endocrinol Invest (2003) 26, 403–6.	12906366
Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, Hering U, Bulitta J, Schreiner P, Sörgel F, Fuhr U. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther (2002) 71, 21–9.	11823754
Haller CA, Jacob P, Benowitz NL. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. Clin Pharmacol Ther (2004) 75, 259–73.	15060505
Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med (2000) 343, 1833–8.	11117974
Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, Rhodes SL, Jungvig L, Gagné J. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA (2003) 280, 1537–45.	12672771
Tormey WP, Bruzzi A. Acute psychosis due to the interaction of legal compounds – ephedra alkaloids in ‘Vigueur Fit’ tablets, caffeine in ‘Red Bull’ and alcohol. Med Sci Law (2001) 41, 331–6.	11693229
Lake CR, Zaloga G, Bray J, Rosenberg D, Chernow B. Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study. Am J Med (1989) 86, 427–32.	2929629
Lake CR, Rosenberg DB, Gallant S, Zaloga G, Chernow B. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther (1990) 47, 675–85.	2357862
Brown NJ, Ryder D, Branch RA. A pharmacodynamic interaction between caffeine and phenylpropanolamine. Clin Pharmacol Ther (1991) 50, 363–71.	1914371
Lake CR. Manic psychosis after coffee and phenylpropanolamine. Biol Psychiatry (1991) 30, 401–4.	1912131
Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med (1990) 89, 195– 208.	2200264
Puig L. Pharmacodynamic interaction with phototoxic plants during PUVA therapy. Br J Dermatol (1997) 136, 973–4.	9217843
Boffa MJ, Gilmour E, Ead RD. Celery soup causing severe phototoxicity during PUVA therapy. Br J Dermatol (1996) 135, 330–45.	8881693
Johne A, Perloff ES, Bauer S, Schmider J, Mai I, Brockmöller J, Roots I. Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. Eur J Clin Pharmacol (2004) 60, 617–22.	15372129
Lilja JJ, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol (2005) 60, 337–41.	16120075
Booth NL, Nikolic D, van Breemen RB, Geller SE, Banuvar S, Shulman LP, Farnsworth NR. Confusion regarding anticoagulant coumarins in dietary supplements. Clin Pharmacol Ther (2004) 76, 511–16.	15592321
Simth L, Ernst E, Ewings P, Myers P, Smith C. Co-ingestion of herbal medicines and warfarin. Br J Gen Pract (2004) 54, 439–41.	15186565
Wong RSM, Cheng G, Chan TYK. Use of herbal medicines by patients receiving warfarin. Drug Safety (2003) 26, 585–8.	12825970
Lambert JP, Cormier A. Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy (2001) 21, 509–12.	11310527
Segal R, Pilote L. Warfarin interaction with Matricaria chamomilla. Can Med Assoc J (2006) 174, 1281–2.	16636327
Yue, Q-Y, Jansson K. Herbal drug Curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. J Am Geriatr Soc (2001) 49, 838.	11454132
Yu CM, Chan JCN, Sanderson JE. Chinese herbs and warfarin potentiation by ‘Danshen’. J Intern Med (1997) 241, 337–9.	9159606
Izzat MB, Yim APC, El-Zufari MH. A taste of Chinese medicine. Ann Thorac Surg (1998) 66, 941–2.	9768962
Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H, Niihara Y. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr (2006) 136 (3 Suppl), 793S–795S.	16484565
German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. Br J Urol (1995) 76, 518.	7551902
Rose KD, Croissant PD, Parliament CF, Levin MP. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery (1990) 26, 880–2.	2352608
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 59, 425–32.	15801937
Krüth P, Brosi E, Fux R, Mörike K, Gleiter CH. Ginger-associated overanticoagulation by phenprocoumon. Ann Pharmacother (2004) 38, 257–60.	14742762
Lesho EP, Saullo L, Udvari-Nagy S. A 76-year-old woman with erratic anticoagulation. Cleve Clin J Med (2004) 71, 651–6 .	15449760
Braun L. Herb-drug interaction guide. Aust Fam Physician (2001) 30, 473–6.	11558205
Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother (2000) 34, 1478–82.	11144706
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 59, 425–32.	15801937
Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology (1998) 50, 1933.	9633781
Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother (2000) 34, 1478–82.	11144706
Mohutsky MA, Anderson GA, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther (2006) 13, 24–31.	16428919
Plotnikoff GA, McKenna D, Watanabe K, Blumenthal M. Ginseng and warfarin interactions. Ann Intern Med (2004) 141, 893–4.	15655860
Zhu M, Chan KW, Ng LS, Chang Q, Chang S, Li RC. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol (1999) 51, 175–80.	10217316
Hopkins MP, Androff L, Benninghoff AS. Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol (1988) 159, 1121–2.	3189445
Greenspan EM. Ginseng and vaginal bleeding. JAMA (1983) 249, 2018.	6834589
Kuo S-C, Teng C-M, Leed J-C, Ko F-N, Chen S-C, Wu T-S. Antiplatelet components in Panax ginseng. Planta Med (1990) 56, 164–7.	2353062
Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health-Syst Pharm (1997) 54, 692–3.	9075501
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 57, 592–99.	15089812
Yuan C-S, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. Brief communication: American ginseng reduces warfarin’s effect in healthy patients. Ann Intern Med (2004) 141, 23–27.	15238367
Hogan RP. Hemorrhagic diathesis caused by drinking an herbal tea. JAMA (1983) 249, 2679–80.	6133016
Wong ALN, Chan TYK. Interaction between warfarin and the herbal product quilinggao. Ann Pharmacother (2003) 37, 836–8.	12773074
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 57, 592–9.	15089812
Yue Q-Y, Bergquist C, Gerdén B. Safety of St John’s wort (Hypericum perforatum). Lancet (2000) 355, 576–7.	11276296
Carr ME, Klotz J, Bergeron M. Coumadin resistance and the vitamin supplement “Noni”. Am J Hematol (2004) 77, 103–4.	15307118
DeMaster EG, Redfern B, Shirota FN, Crankshaw DL, Nagasawa HT. Metabolic activation of n-butyraldoxime by rat liver microsomal cytochrome P450. A requirement for the inhibition of aldehyde dehydrogenase. Biochem Pharmacol (1993) 46, 117–23.	8347123
Rostami-Hodjegan A, Shiran MR, Ayesh R, Grattan TJ, Burnett I, Darby-Dowman A, Tucker GT. A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. A four-way crossover study to compare the concentration-time profile of paracetamol from the new paracetamol/sodium bicarbonate tablet and a conventional paracetamol tablet in fed and fasted volunteers. Drug Dev Ind Pharm (2002) 28, 523–31.	12098842
